Meta-analysis of coagulation disbalances in COVID-19: 41 studies and 17601 patients

Polina Len¹, Gaukhar Iskakova^{1,#}, Zarina Sautbayeva^{1,#}, Aigul
 Kussanova^{1,2,#}, Ainur T. Tauekelova³, Madina M. Sugralimova³, Anar S.
 Dautbaeva³, Meruert M. Abdieva³, Eugene D. Ponomarev⁴, Alexander

4 Tikhonov¹, Makhabbat S. Bekbossynova^{3,*}, Natasha S. Barteneva^{1,5,6*}

- ¹School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan
- ²Core Facilities, Nazarbayev University, Nur-Sultan, Kazakhstan
- ⁷ ³National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan
- ⁴School of Biomedical Sciences, Chinese University of Hong Kong, Shatin. Hong Kong
- ⁵National Laboratory Astana, Nur-Sultan, Kazakhstan
- ⁶Brigham and Women's Hospital, Harvard Medical School, Boston, USA
- [#]These authors made an equal contribution in the study
- 12 *Joint senior authors
- 13
- 14 Keywords: COVID-19; coagulopathy; thrombosis; D-dimers; platelets; fibrinogen; immature
- 15 reticulated platelets; prothrombin time

17 Abstract

Introduction. Coagulation parameters are important determinants for COVID-19 infection.
We conducted meta-analysis to assess the early hemostatic parameters in retrospective
studies in association with severity of infection.

21 Methods. Ovid, PubMed, Web of Sciences, and Google Scholar were searched for research 22 articles that addressed clinical characteristics of COVID-19 patients and disease severity. 23 Results were filtered using exclusion and inclusion criteria and then pooled into a meta-24 analysis to estimate the standardized mean difference with 95% CI for each of five 25 coagulation parameters (D-dimers, fibrinogen, prothrombin time, platelets count, activated 26 partial thromboplastin time). Two authors independently extracted data and assessed study 27 quality. To explore the heterogeneity and robustness of our fundings, sensitivity and 28 subgroup analyses were conducted. Publication bias was assessed with contour-enhanced 29 funnel plots and Egger test by linear regression.

30 Results. Overall, 41 original studies (17601 patients) on SARS-CoV2 were included. For the 31 two groups of patients, stratified by severity, we identified that D-dimers, fibrinogen, 32 activated partial thromboplastin time, and prothrombin time were significantly higher in the 33 severe group (SMD 0.6985 with 95%CI [0.5155; 0.8815]); SMD 0.661with 95%CI [0.3387; 34 0.9833]; SMD 0.2683 with 95%CI [0.1357; 0.4009]; SMD 0.284 with 95%CI [0.1472; 0.4208]). In contrast, PLT was significantly lower in patients with more severe cases of 35 36 COVID-19 (SMD -0.1684 with 95%CI [-0.2826; -0.0542]). Neither the analysis by the leave-37 one-out method nor the influence diagnostic have identified studies that solely cause 38 significant change in the effect size estimates. Subgroup analysis showed no significant 39 difference between articles originated from different countries but revealed that severity 40 assessment criteria might have influence over estimated effect sizes for platelets and D-

| 41 | dimers. Contour-enhanced funnel plots and the Egger test for D-dimers and fibrinogen |
|----|---|
| 42 | revealed significant asymmetry that might be a sign of publication bias. |
| 43 | Conclusions. The standard coagulation laboratory parameters with exception of platelets |
| 44 | counts are significantly elevated in patients with severe COVID-19. However, fibrinolysis |
| 45 | shutdown requires evaluation outside conventional coagulation tests and analysis of |
| 46 | additional specific markers related to clotting formation and PLT characteristics. We |
| 47 | hypothesize that a proportion and parameters of immature reticulated platelets may serve as |
| 48 | additional biomarkers for prediction of adverse events. |
| 49 | |
| 50 | |
| 51 | |
| 52 | |
| 53 | |
| 54 | |
| 55 | |
| 56 | |
| 57 | |
| 58 | |
| 59 | |
| 60 | |
| 61 | |
| 62 | |
| 63 | |
| 65 | |
| 66 | |
| | |

67 **1** Introduction

In less than two years of the outbreak, the COVID-19 pandemic took almost five million lives (John Hopkins, 2021). SARS-CoV-2 is the seventh member of the large coronavirus family capable of inducing human disease (Carsana et al., 2020). Viral respiratory infections, including severe respiratory acute syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 may induce coagulopathy and lead to intravascular thrombi and deposition of fibrinogen (Hwang et al., 2005; Yang et al., 2005; Goeijenbier et al., 2012; WHO MERS guidelines, 2013; Giannis et al., 2020).

75 The coagulation system is activated and dysregulated during COVID-19 infection; however, characteristics of COVID-19 associated coagulopathy are different from coagulation 76 77 disorders (Iba et al., 2020). Evidence of abnormal COVID-19-associated coagulation 78 parameters appeared already in early publications from Wuhan (Chen et al., 2020; Wang et 79 al., 2020; Zhou et al., 2020) and was supported by further publications worldwide (rev. Levi 80 et al., 2020; Iba et al., 2020). The reported hemostatic abnormalities with COVID-19 81 infection include increased D-dimers levels (Lippi et al., 2020; Demelo-Rodriguez et al., 82 2020), fibrinogen levels (Ranucci et al., 2020; Panigada et al., 2020), changes in the 83 quantities and levels of activation of platelets (Yang et al., 2020; Lippi et al., 2020; Hottz et 84 al., 2020; Althaus et al., 2021), elevated von Willebrand factor (Goshua et al., 2020; 85 Doevelaar et al., 2021, rev. by Becker et al., 2021) and other coagulation parameters. 86 Persistently elevated thrombocytic events, even with initiation of prophylactic anti-87 coagulation, suggest the presence of hypofibrinolysis in addition to detected 88 hypercoagulability in COVID-19 (Creel-Bulos et al., 2021; Bachler et al., 2021). It is also 89 consistent with results of thromboelastography (TEG) reported by Wright et al. (2020).

90 There is a need in early detection of elevated coagulation biomarkers to optimize risk91 stratification of patients with COVID-19. However, due to limitations of early pandemic

92 research with small study sizes and highly heterogeneous datasets it is still debated. The aim 93 of the current study was to evaluate the validity of stratification based on early coagulation 94 parameters provided by different clinical studies worldwide. We also aimed to use subgroup 95 analysis to explore whether heterogeneity in results was in part explained by differences in 96 patient subpopulations. Finally, the coagulation parameters of our own cohort were included 97 in a systematic meta-analysis of published studies.

98 2 Materials and Methods

In this study, we aimed to identify the relationship between coagulation biomarkers taken at admission and severity of COVID-19 in adult (>18) patients by estimating the effect size of five laboratory coagulation tests: D-dimers, platelets, fibrinogen, activated partial thromboplastin time, and prothrombin time.

103 2.1 Search Strategy, Exclusion and Inclusion criteria

104 To broaden our search, we included Ovid, PubMed, Web of Sciences, and Google Scholar 105 in the study. They were thoroughly scanned using the following keywords: SARS-CoV-2, 106 COVID-19, coagulation, severity, characteristics, features, D-dimers, platelets, fibrinogen, 107 cohort, observational, retrospective. First, satisfying search results were exported to an Excel 108 table and duplicates were eliminated. Second, we conducted a preliminary review of retrieved 109 articles' abstracts. Papers that focused on pregnant women, children, or specific age groups 110 were avoided. Similarly, works that focused on the effect of medical treatment or patients 111 with particular commodities were not included in the meta-analysis. We also excluded studies 112 that compared mortality among groups of COVID-19 patients. Then, each publication was 113 checked according to the inclusion criteria: sample size, severity assessment criteria, presence 114 of at least one coagulation marker of interest expressed as a continuous variable. To be 115 included, a study should have had more than 15 patients and divided them according to the

116 disease severity - WHO guidelines, ICU admission, disease aggravation, or need for oxygen 117 therapy. Next, a list of biomarkers should have included at least some of the coagulation parameters: platelets count (PLT), D-dimers (DD), fibrinogen (FIB), activated partial 118 119 thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), Activated 120 thrombin (AT), Factor VIII (FVIII), and Von Willebrand factor (vWF). Finally, the quality of 121 selected articles was assessed with the NIH Quality Assessment Tool for Observational 122 Cohort and Cross-Sectional studies. Questions 5, 6, 12, 13 were not applicable to selected 123 studies due to their observational/retrospective nature; Question 8 was not applicable to 124 studies with dichotomous exposure values, like ICU admission and need for oxygen therapy. 125 Hence, studies with a quality score of less than five were excluded from the analysis. Search, 126 and quality check were conducted independently by two authors. Disagreements were 127 resolved during a joint discussion with a third author.

128 2.2 Data extraction

The primary goal was to retrieve from each article data about two groups of patients differing by disease severity: group size, stratification criteria, results of the laboratory tests. Apart from these, we kept a record of the country, hospital, and admission time in order to identify and exclude duplicate patients.

133 **2.3** Cohort from the National Research Center for Cardiac Surgery

134 2.3.1 Participants and data collection

From a large cohort of 560 patients consecutively admitted from June 2020 to August 2021 due to coronavirus infection to the cardiology department of the NCJSC "National Research Center for Cardiac Surgery" (NRCCS), Nur-Sultan, Kazakhstan, we selected 451 patients with a confirmed diagnosis of COVID-19, aged \geq 18 years, and those with the onset of the disease \leq 21 days, all of whom were hospitalized for at least 24 hours with COVID-19. All

140 demographic, clinical, laboratory data were extracted from the electronic records of the 141 NRCSC. Laboratory tests included PLT, PT, international normalized ratio, APTT, FIB, DD. 142 Blood samples were collected at admission by the clinical team. Clotting tests were 143 performed according to standard methods. For coagulation tests (PT, international normalized 144 ratio, APTT, FIB), we used AVATUBE® with sodium citrate, and it was measured on 145 Sysmex CS-2500 (Sysmex, Japan). Blood for DD was collected in AVATUBE® with 146 sodium citrate, and D-dimers were quantified on Cobas® 6000. PLT counts were measured 147 on Sysmex XS-500 (Sysmex, Japan) with blood collection performed in AVATUBE® with 148 K2 EDTA. The confirmation of SARS-CoV-2 infection was done by real-time quantitative 149 reverse-transcription polymerase chain reaction (RT-PCR) assay on nose/throat swab or 150 sputum samples using CFX96® Real-Time System (Bio-Rad Laboratories, Inc., USA).

151 **2.3.2 Clinical assessment**

The COVID-19 population was initially divided into four groups according to disease severity following local guidelines "Diagnosis and treatment of Covid-19 in Adults" (http://www.rcrz.kz/index.php/ru/2017-03-12-10-51-13/klinicheskie-protokoly) (**Suppl. File** 1). The study protocol was approved by the medical ethics committee of the National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan waiving the need for written informed consent due to the retrospective design.

158 2.4 Data analysis

159 **2.4.1 Data transformation**

All data analysis was performed in the RStudio 1.4.1717 with R version 4.1.0 (Integrated Development Environment for R. RStudio, PBC, USA). In the most of cases, results were reported as the first, second (median), and third quartiles, reflecting that original data was not normally distributed. The "estmeansd" package was used to convert median, interquartile range, minimum and maximum values to mean and standard deviation. The package

implements Box Cox transformation to normalize raw data prior to conversion. Then, Lou (2018) formulas for mean and Wan (2014) formulas for standard deviation are used. Since the criteria and number of groups differed from study to study, patients had to be regrouped into the more and less severe groups accordingly: severe/critical and mild/moderate, ICU admitted patients and outpatients/general ward patients, observed aggravation and recovery/stable, and need for oxygen therapy.

171 **2.4.2 Meta-analysis**

172 The "meta" and "metafor" packages were used for the meta-analysis. Heterogeneity was 173 assessed using the I^2 , tau-squared, and prediction intervals. Following the recommendations 174 of Veroniki (2016), Paule-Mandel (PM) tau-squared estimator and Q-Profile (QP) tau-175 squared confidence interval estimator were used in this meta-analysis. To account for 176 different measurement scales and possible inaccuracy of the Graph Digitizer, the standardized 177 mean difference (SMD), or Hedges g, based on the inverse-variance approach, was estimated. 178 For datasets with high heterogeneity, the Knapp-Hartung adjusted random-effects model is 179 implemented. In case of low heterogeneity, the fixed-effects model is applied.

180 **2.4.3 Sensitivity and Subgroup analysis**

We also performed several sensitivity analyses using the "dmetar" package. First, we recalculated the effect size using the leave-one-out method. Second, basic outliers, studies whose confidence intervals do not overlap with the pooled effect confidence interval, were removed. Third, we ran the diagnostic for influential cases with Graphic Display of Study Heterogeneity (GOSH) plots and excluded them from the meta-analysis. To further explore the heterogeneity of the data, we conducted subgroup analyses: based on grouping criteria and location.

188 **2.5 Publication Bias**

- 189 We used the counter-enhanced Funnel plots and Egger's test by linear regression to assess
- 190 the possibility for publication bias in selected studies.



191

Figure 1. Flow diagram illustrating the process of data collection.

193

194 **3 Results**

195 **3.1 Results of the Web Search**

The stepwise process of selection is depicted in Figure 1. Initially, there were 4056 papers that matched search parameters. After the removal of duplicates and studies that did not meet the exclusion criteria, only 195 unique studies remained. A more thorough review based on the inclusion criteria has proven 125 studies to be unfitting. In addition to 70 that were left,

15 studies were extracted from the references lists of previously published meta-analyses and
systematic reviews. Finally, we performed a quality check and removed duplicate patients,
which resulted in 40 being included into the meta-analysis. Besides original articles, we have
included data from the National Research Center for Cardiac Surgery located in Nur-Sultan,
Kazakhstan. This data set included data from 451 patients with acute COVID-19.

3.2 Description of Selected Studies

Overall, this meta-analysis comprises 17601 patients from 40 research papers and the NRCSC. Of the total, 24 studies originated from China, while the rest included data from France, Germany, Italy, Mexico, Singapore, South Korea, Turkey, UK, and the USA. Most of the articles (23) reported division of patients according to the WHO guidelines. Out of the rest, 12 articles made groups based on the ICU admission, 3 focused on disease aggravation, and 3 on the need for oxygen therapy. This information is depicted in **Figure 2** in more detail.





Figure 2. Diagram depicting characteristics of selected studies: (A) number of publications per country, (B) number of patients per country, (C) number of publications per severity assessment criterion. The latter (C) indicates the total number of research articles to be 42 instead of 41 because one study reported two populations of patients admitted to the hospital at different periods.

219 3.3 Results of Meta-analysis

220 **3.3.1 Pooled Effect Sizes**

221 We collected data for five coagulation parameters: PLT, DD, FIB, APTT, and PT. In all cases, the heterogeneity was extremely high ($I^2 > 80\%$), so the Knapp-Hartung adjusted 222 223 random-effects model was applied in all parts of the meta-analysis. DD, FIB, APTT, and PT 224 were significantly higher in more severe cases (SMD 0.6985 with 95%CI [0.5155; 0.8815]; 225 SMD 0.661 with 95%CI [0.3387; 0.9833]; SMD 0.2683 with 95%CI [0.1357; 0.4009]; SMD 226 0.284 with 95%CI [0.1472; 0.4208]). In contrast, PLT was significantly lower in patients 227 with severe cases of COVID-19 (SMD -0.1684 with 95%CI [-0.2826; -0.0542]). Forest plots 228 for the meta-analyses are shown in **Figures 3-4**, and results are highlighted in **Table 1**. 229

230

231

| | | More | Severe | | Less | Severe | Standardised Mean | | | |
|---|-------------|---------|---------|-------|--------|--------|-------------------|-------|----------------|--------|
| Study | Total | Mean | SD | Total | Mean | SD | Difference | SMD | 95%-CI | Weight |
| X Zheng et al | 28 | 156.70 | 42.40 | 52 | 215.30 | 66.40 | | -0.98 | [-1.47; -0.50] | 2.3% |
| Noh et al | 26 | 182.76 | 70.07 | 239 | 236.79 | 68.17 | | -0.79 | [-1.20; -0.38] | 2.7% |
| Bergantini et al | 10 | 183.70 | 62.00 | 14 | 278.00 | 156.00 | | -0.72 | [-1.56: 0.12] | 1.2% |
| Zhou et al | 28 | 157.50 | 23.00 | 95 | 184.00 | 42.00 | | -0.68 | [-1.11: -0.25] | 2.6% |
| Gerotziafas et al (1) | 102 | 204.48 | 59.65 | 208 | 257.56 | 105.89 | | -0.57 | [-0.81: -0.33] | 3.5% |
| Jiao Liu et al | 261 | 170.77 | 88.94 | 841 | 216.42 | 80.93 | | -0.55 | [-0.69: -0.41] | 4.0% |
| Wliuetal | 11 | 143 90 | 64 81 | 67 | 173 20 | 55.37 | | -0.51 | [-1.15: 0.13] | 1.7% |
| Jie Liu et al | 152 | 190.96 | 82 66 | 62 | 229 38 | 77.29 | | -0.47 | 1-0.77 -0.171 | 3.2% |
| Shang et al | 139 | 200.97 | 83.38 | 304 | 239.28 | 91.51 | - | -0.43 | [-0.63: -0.23] | 3.7% |
| J Zhao et al | 84 | 163 20 | 34 84 | 499 | 186 55 | 57 79 | - | -0.42 | [-0.66: -0.19] | 3.6% |
| P Wang et al | 18 | 227 51 | 52 10 | 101 | 261.41 | 95.46 | | -0.37 | [-0.88: 0.13] | 2.2% |
| Ding et al | 30 | 166 17 | 66.88 | 281 | 189 66 | 63 73 | | -0.37 | [-0.74: 0.01] | 2.8% |
| G Zhang et al | 55 | 161.83 | 36.83 | 166 | 175 38 | 56 52 | | -0.26 | [-0.56 0.05] | 3.2% |
| Cuono et al | 46 | 260.37 | 130.35 | 102 | 307 13 | 207 68 | | -0.25 | [-0.60: 0.10] | 3.0% |
| Rauch et al | 71 | 214 00 | 98.00 | 172 | 236.00 | 120.00 | | -0.19 | [-0.47: 0.08] | 3 3% |
| N Chen et al | 75 | 159 60 | 69.61 | 186 | 169.00 | 62.85 | | -0.14 | [-0.41: 0.12] | 3 4% |
| Higuera-de-la-Tijera et al | 27 | 210 70 | 73.10 | 120 | 226.40 | 86.20 | - | -0.08 | [-0.49: 0.22] | 2 7% |
| O Chen et al | 43 | 213 18 | 99.61 | 102 | 217 45 | 60.77 | | -0.06 | [-0.41: 0.30] | 2 9% |
| Bauer et al | 7 | 199 38 | 43 15 | 10 | 202 30 | 64 27 | | -0.05 | [-1.01: 0.92] | 1.0% |
| Y Zhao et al | 74 | 253.02 | 122.61 | 211 | 258 08 | 105 16 | | -0.05 | [-0.31: 0.22] | 3.4% |
| Young et al | 6 | 162 45 | 39 42 | 12 | 163 54 | 25.16 | | -0.03 | [-1.01: 0.95] | 1.0% |
| I Zhang et al | 209 | 209 57 | 142.08 | 252 | 213 11 | 82 79 | - | -0.03 | [-0.21: 0.15] | 3.8% |
| 7 Chen et al | 43 | 222 08 | 123 54 | 158 | 223 15 | 87.63 | | -0.01 | [-0.35: 0.33] | 3.0% |
| Mikami et al | 3708 | 224 77 | 88 25 | 2785 | 223.09 | 84 28 | | 0.02 | [-0.03: 0.07] | 4.2% |
| Gerotziafas et al (2) | 31 | 269 98 | 85 86 | 89 | 267 56 | 96.91 | | 0.03 | [-0.38: 0.43] | 2 7% |
| Lonez-Castaneda et al | 64 | 294 07 | 117 50 | 37 | 287 88 | 104.80 | | 0.05 | [-0.35: 0.46] | 2 7% |
| Yu et al | 864 | 247 43 | 105 70 | 799 | 239 40 | 109.15 | | 0.07 | [-0.02 0.17] | 4 1% |
| NRCSC | 110 | 227 44 | 116 70 | 340 | 217 41 | 89 79 | - | 0.10 | [-0.11: 0.32] | 3 7% |
| Liao et al | 231 | 216 64 | 161 71 | 149 | 197.82 | 73 47 | — | 0.14 | [-0.07: 0.35] | 3 7% |
| Con et al | 244 | 226.41 | 08 14 | 400 | 211 03 | 80.73 | | 0.17 | [0.01: 0.32] | 3.0% |
| Karakowa at al | 94 | 264 70 | 146.01 | 112 | 242 60 | 96.64 | | 0.19 | [-0.10: 0.47] | 3 304 |
| Reetuo et al | 46 | 262 97 | 146.67 | 145 | 242.00 | 107.66 | | 0.10 | [-0.15: 0.52] | 3 1% |
| H 7bana at al | 40 | 202.97 | 137 60 | 20 | 101 67 | 81 70 | | 0.19 | [-0.37: 0.01] | 1 7% |
| White et al | 75 | 288.00 | 138.00 | 34 | 221.00 | 87.00 | | 0.53 | [0.12; 0.95] | 2.7% |
| Random effects model | 7016 | | | 9202 | | | • | -0.17 | [-0.28; -0.05] | 100.0% |
| Prediction interval | | | | | | | | | [-0.74; 0.40] | |
| Heterogeneity: $l^2 = 82\%$ $\tau^2 = 0.07$ | 743 10 0375 | 0 15591 | n < 0.0 | 1 | | | | | | |

B D-dimer

A Platelets

| Shang et al lauer et al u et al | 139 | Mean | SD | Total | 10000 | 60 | Difference | SMD | 95%-CI | Mainh |
|--|------|----------|-----------|-------|---------|---------|------------|--------|----------------|-------|
| Shang et al lauer et al 'u et al | 139 | | | iotui | Wean | 50 | Difference | SIND | 3070 01 | weigi |
| Bauer et al ju et al | | 856.31 | 1008.98 | 304 | 2945.91 | 7518.31 | - | -0.33 | [-0.54; -0.13] | 3.09 |
| u et al | 7 | 971.17 | 283.25 | 10 | 1132.30 | 563.65 | | -0.32 | [-1.30: 0.65] | 1.6 |
| | 16 | 1946.22 | 5627.75 | 59 | 2103.70 | 8107.84 | | -0.02 | [-0.57; 0.53] | 2.49 |
| lauch et al | 71 | 1432.83 | 1000.18 | 172 | 1400.20 | 1074.70 | | 0.03 | [-0.25: 0.31] | 2.9 |
| hou et al | 28 | 370.00 | 150.00 | 95 | 300.00 | 460.00 | | 0.17 | [-0.25: 0.59] | 2.6 |
| Serotziafas et al (2) | 31 | 2487.64 | 932.44 | 89 | 2334.31 | 588.12 | | 0.22 | [-0.19: 0.63] | 2.6 |
| Aikami et al | 3708 | 2513,10 | 2929.05 | 2785 | 1906.08 | 2426.98 | - | 0.22 | [0.17: 0.27] | 3.1 |
| 'u et al | 864 | 1541.71 | 2045.94 | 799 | 1089.75 | 1316.61 | | 0.26 | [0.16: 0.36] | 3.1 |
| Aicco et al | 31 | 980.44 | 738.19 | 54 | 773.91 | 668.09 | | 0.29 | [-0.15: 0.74] | 2.6 |
| ong et al | 76 | 2546.32 | 5982 55 | 39 | 850.00 | 1680.00 | | 0.34 | [-0.05: 0.73] | 2.7 |
| Cen et al | 244 | 3878.50 | 13263.42 | 409 | 873.72 | 1087.93 | | 0.37 | [0.21: 0.53] | 3.0 |
| Chen et al | 43 | 395.56 | 272.95 | 102 | 307.62 | 219.61 | | 0.37 | [0.01: 0.73] | 2.7 |
| iao Liu et al | 261 | 18837.21 | 97339.85 | 841 | 1158.83 | 1393.82 | | 0.37 | [0.23: 0.51] | 3.0 |
| V Liu et al | 11 | 41945.80 | 280801.29 | 67 | 956.25 | 1583.88 | | 0.40 | [-0.24: 1.04] | 2.2 |
| Vhite et al | 75 | 2137.55 | 4624.70 | 34 | 462.17 | 442.55 | | 0.43 | [0.02: 0.84] | 2.6 |
| ie Liu et al | 152 | 11952 07 | 27966 64 | 62 | 1371.85 | 1736.96 | | 0.45 | [0.15: 0.74] | 2.8 |
| Zheno et al | 28 | 165.80 | 128.10 | 52 | 102.10 | 102.10 | | 0.56 | [0.10: 1.03] | 2.5 |
| Serotziafas et al (1) | 102 | 2946 38 | 3114.77 | 208 | 1673 35 | 1600.76 | | 0.57 | [0.33: 0.81] | 29 |
| Cunno et al | 46 | 6544 65 | 14441 02 | 102 | 1611.06 | 1829.37 | | 0.60 | [0.25: 0.96] | 27 |
| Suleyman et al | 141 | 2642.85 | 3335 59 | 214 | 1258 73 | 1040 50 | | 0.61 | [0.40: 0.83] | 3.0 |
| onez=Castaneda et al | 64 | 2840.00 | 3900.00 | 37 | 822 10 | 600.00 | | 0.64 | [0.22: 1.05] | 2.6 |
| Zhao et al | 74 | 1318 16 | 2082.65 | 211 | 528 04 | 444 27 | | 0.70 | [0.43: 0.97] | 29 |
| RCSC | 109 | 2895 78 | 5469 52 | 330 | 609 53 | 967 84 | | 0.81 | [0.59 1.03] | 2.0 |
| Zhang et al | 55 | 1256 45 | 2375 13 | 166 | 257 11 | 214 38 | | 0.83 | [0.52: 1.15] | 2.8 |
| Zhang et al | 14 | 7394 40 | 14416.61 | 29 | 375.81 | 225.80 | | 0.85 | [0.18: 1.51] | 21 |
| Chen et al | 75 | 842.00 | 1343.83 | 186 | 180.00 | 330.00 | | 0.86 | [0.58: 1.13] | 29 |
| lastun et al | 46 | 2082 42 | 2120 33 | 145 | 766.47 | 864.89 | | 1.02 | [0.68: 1.37] | 2.8 |
| Vang et al | 18 | 688 30 | 804 23 | 49 | 222 78 | 102 31 | | 1.00 | [0.52: 1.67] | 23 |
| iao et al | 231 | 4083 14 | 3771 46 | 140 | 767 68 | 1003.03 | - | 1.00 | [0.88: 1.32] | 2.0 |
| liquera et al | 201 | 7765.00 | 9109.00 | 130 | 1971.00 | 4146.00 | | 1 12 | [0.60; 1.52] | 2.0 |
| Chen et al | 43 | 2352.91 | 3521 47 | 158 | 411 16 | 203.41 | | 1 19 | [0.83: 1.55] | 2.0 |
|)ing et al | 30 | 1203 74 | 1223 53 | 281 | 540.82 | 396.83 | | - 1.13 | [1.02: 1.80] | 2.1 |
| Zhao et al | 84 | 1203.46 | 305.00 | 400 | 605 78 | 448.95 | | 1.62 | [1.37: 1.86] | 20 |
| Zhao et al | 200 | 2764 20 | 2509.00 | 499 | 747.26 | 574.02 | | 1.02 | [1.37, 1.00] | 2.5 |
| Zhang et al | 10 | 2072 12 | 2000.00 | 101 | 650 59 | 379.13 | | 1.00 | [1.47, 1.03] | 3.0 |
| wangetai | 10 | 1425 22 | 3030.59 | 101 | 467.07 | 422.40 | | 1.00 | [1.13; 2.23] | 2.4 |
| loisio et al | 47 | 21194.06 | 24598.98 | 322 | 3337.35 | 5901.13 | | • 1.73 | [1.40; 2.06] | 2.5 |
| Random effects model | 7238 | | | 9720 | | | • | 0.70 | [0.52; 0.88] | 100.0 |

233

Figure 3. Forest plot of association between COVID-19 severity and platelets (A), D-dimers

235 **(B**).

| | M | ore Se | vere | L | ess Se | vere | Standardised Mean | | | |
|-----------------------|-------|--------|------|-------|--------|------|-------------------|--------|---------------|--------|
| Study | Total | Mean | SD | Total | Mean | SD | Difference | SMD | 95%-CI | Weight |
| N Chen et al | 75 | 4.67 | 1.43 | 186 | 4.79 | 1.41 | | -0.09 | [-0.35; 0.18] | 4.8% |
| Cugno et al | 46 | 5.31 | 2.08 | 102 | 5.41 | 1.70 | | -0.05 | [-0.40; 0.29] | 4.7% |
| Lopez-Castaneda et al | 64 | 6.26 | 2.15 | 37 | 6.30 | 1.44 | - | -0.02 | [-0.43; 0.38] | 4.6% |
| Liao et al | 231 | 4.47 | 1.66 | 149 | 4.38 | 1.35 | | 0.05 | [-0.15; 0.26] | 4.9% |
| Bauer et al | 7 | 5.12 | 1.17 | 10 | 5.02 | 1.03 | | 0.09 | [-0.88; 1.06] | 3.3% |
| Higuera et al | 27 | 6.40 | 2.07 | 139 | 6.08 | 1.68 | - | 0.18 | [-0.23; 0.59] | 4.6% |
| Rauch et al | 71 | 6.40 | 1.50 | 172 | 5.90 | 1.70 | - | 0.30 | [0.03; 0.58] | 4.8% |
| Mikami et al | 3708 | 6.40 | 1.82 | 2785 | 5.85 | 1.49 | | 0.33 | [0.28; 0.37] | 5.0% |
| Ding et al | 30 | 4.84 | 0.92 | 281 | 4.38 | 1.23 | - | 0.37 | [0.00; 0.75] | 4.6% |
| Gerotziafas et al (2) | 31 | 6.86 | 1.31 | 89 | 6.22 | 1.57 | - | 0.42 | [0.00; 0.83] | 4.6% |
| NRCSC | 111 | 5.20 | 1.73 | 340 | 4.39 | 1.43 | | 0.54 | [0.32; 0.75] | 4.9% |
| Zhou et al | 28 | 2.75 | 0.76 | 95 | 2.50 | 0.30 | | 0.56 | [0.13; 0.98] | 4.5% |
| Gerotziafas et al (1) | 102 | 6.71 | 1.19 | 208 | 5.82 | 1.67 | | 0.58 | [0.34; 0.82] | 4.8% |
| Z Chen et al | 43 | 4.52 | 1.18 | 158 | 3.52 | 1.46 | - | 0.71 | [0.36; 1.05] | 4.7% |
| H Zhang et al | 14 | 4.70 | 1.98 | 29 | 3.50 | 1.35 | | 0.75 | [0.09; 1.41] | 4.0% |
| J Zhang et al | 209 | 4.60 | 1.68 | 252 | 3.42 | 1.13 | | 0.84 | [0.65; 1.03] | 4.9% |
| X Zheng et al | 28 | 3.60 | 0.80 | 52 | 2.90 | 0.80 | | 0.87 | [0.39; 1.35] | 4.4% |
| Bastug et al | 46 | 4.54 | 1.42 | 145 | 3.60 | 0.91 | | 0.89 | [0.55; 1.24] | 4.7% |
| White et al | 75 | 6.42 | 2.01 | 34 | 4.33 | 1.28 | | 1.14 | [0.71; 1.58] | 4.5% |
| J Zhao et al | 84 | 4.90 | 1.85 | 499 | 3.50 | 1.01 | | 1.19 | [0.95; 1.43] | 4.8% |
| Wang et al | 18 | 6.27 | 1.09 | 49 | 4.00 | 0.84 | _ | 2.47 | [1.77; 3.16] | 4.0% |
| Fu et al | 16 | 1.57 | 0.39 | 59 | 0.94 | 0.12 | - | - 3.02 | [2.28; 3.76] | 3.8% |
| Random effects model | 5064 | | | 5870 | | | - | 0.66 | [0.34; 0.98] | 100.0% |
| Prediction interval | | | | | | | | | [-0.82; 2.14] | |

B Activated partial thromboplastin time

| | | WOIG | Severe | | L622 C | evere. | Stanuaruiseu mean | | | |
|----------------------------|---------------------|----------|----------|----------|--------|--------|--------------------------------|--------|----------------|--------|
| Study | Total | Mean | SD | Total | Mean | SD | Difference | SMD | 95%-CI | Weight |
| H Zhang et al | 14 | 25.13 | 2.97 | 29 | 26.93 | 2.49 | | -0.67 | [-1.32; -0.01] | 2.4% |
| J Zhao et al | 84 | 31.80 | 6.34 | 499 | 33.19 | 6.93 | | -0.20 | [-0.43; 0.03] | 5.8% |
| Yu et al | 864 | 39.14 | 5.21 | 799 | 39.42 | 5.30 | | -0.05 | [-0.15: 0.04] | 6.9% |
| Bastug et al | 46 | 25.00 | 2.29 | 145 | 25.02 | 3.21 | | -0.01 | [-0.34; 0.33] | 4.8% |
| Rauch et al | 71 | 1.15 | 0.13 | 172 | 1.13 | 0.19 | | 0.07 | [-0.21: 0.35] | 5.3% |
| Micco et al | 31 | 1.01 | 0.17 | 54 | 1.00 | 0.14 | | 0.08 | [-0.36: 0.52] | 3.8% |
| X Zheng et al | 28 | 31.30 | 3.90 | 52 | 30,70 | 3.10 | | 0.17 | [-0.29; 0.64] | 3.6% |
| White et al | 75 | 33.70 | 5.00 | 34 | 32.60 | 3.80 | | 0.23 | [-0.17; 0.64] | 4.1% |
| Karakovun et al | 84 | 25.89 | 4.30 | 113 | 25.08 | 2.30 | | 0.24 | [-0.04: 0.53] | 5.3% |
| Q Chen et al | 43 | 30.59 | 3.48 | 102 | 29.71 | 3.14 | | 0.27 | [-0.09; 0.63] | 4.5% |
| G Zhang et al | 55 | 31.96 | 4.48 | 166 | 31.04 | 2.96 | | 0.27 | [-0.03; 0.58] | 5.0% |
| Cugno et al | 46 | 1.03 | 0.26 | 102 | 0.98 | 0.13 | | 0.29 | [-0.06; 0.64] | 4.6% |
| Jiac Liu et al | 79 | 29.41 | 7.24 | 43 | 27.39 | 5.38 | | 0.30 | [-0.07; 0.67] | 4.4% |
| Long et al | 76 | 36,66 | 8.99 | 39 | 33,49 | 9.17 | | 0.35 | [-0.04; 0.74] | 4.2% |
| Liao et al | 231 | 39.77 | 7.91 | 149 | 36.70 | 4.75 | | 0.45 | [0.24; 0.65] | 6.0% |
| Z Chen et al | 43 | 36.65 | 9.62 | 158 | 32.78 | 7.07 | | 0.50 | [0.16: 0.84] | 4.7% |
| NRCSC | 111 | 49.46 | 34.10 | 338 | 37.70 | 14.04 | | 0.56 | [0.35: 0.78] | 5.9% |
| Jiao Liu et al | 261 | 31.23 | 7.75 | 841 | 27.71 | 5.53 | | 0.57 | [0.43; 0.72] | 6.6% |
| J Zhang et al | 209 | 32.44 | 6.14 | 252 | 29.76 | 2.68 | | 0.58 | [0.40; 0.77] | 6.2% |
| Ding et al | 30 | 42.06 | 5.99 | 281 | 39.01 | 4.34 | | 0.67 | [0.29; 1.05] | 4.3% |
| Bauer et al | 7 | 100.54 | 135.96 | 10 | 32.99 | 2.68 | 19 11 1912 1 91 | → 0.75 | [-0.26; 1.75] | 1.3% |
| Random effects model | 2488 | | | 4378 | | | - | 0.27 | [0.14; 0.40] | 100.0% |
| Prediction interval | | | | | | _ | | _ | [-0.24; 0.78] | |
| Heterogeneity: /2 = 83%, 7 | ² = 0.05 | 58 [0.02 | 28; 0.15 | 77], p · | < 0.01 | | | | | |
| | | 2 | | | | -1.5 | -1 -0.5 0 0.5 1 | 1.5 | | |

C Prothrombin time

| | | More S | Severe | L | ess Se | vere | Standardised Mean | | | | |
|-----------------------|-------|--------|--------|-------|--------|------|-------------------|-------|------------|-------|--------|
| Study | Total | Mean | SD | Total | Mean | SD | Difference | SMD | 95% | 6-CI | Weight |
| Zhou et al | 28 | 15.80 | 1.20 | 95 | 16.20 | 0.60 | | -0.51 | [-0.94; -0 | 0.09] | 3.5% |
| Cugno et al | 46 | 1.15 | 0.11 | 102 | 1.25 | 0.40 | | -0.31 | [-0.66; (| 0.04] | 4.0% |
| J Zhao et al | 84 | 12.25 | 1.28 | 499 | 12.51 | 1.04 | | -0.24 | [-0.47; -0 | 0.01] | 4.7% |
| Gerotziafas et al (2) | 31 | 14.80 | 1.99 | 89 | 14.61 | 1.65 | | 0.11 | [-0.30; (| 0.52] | 3.6% |
| Rauch et al | 71 | 1.11 | 0.10 | 172 | 1.10 | 0.09 | | 0.14 | [-0.14; (| 0.42] | 4.4% |
| Ding et al | 30 | 13.50 | 0.86 | 281 | 13.40 | 0.59 | | 0.15 | [-0.22; (| 0.53] | 3.8% |
| Q Chen et al | 43 | 11.98 | 0.80 | 102 | 11.85 | 0.82 | | 0.15 | [-0.20; (| 0.511 | 3.9% |
| Long et al | 76 | 12.71 | 2.35 | 39 | 12.34 | 1.91 | | 0.17 | [-0.22; (| 0.55] | 3.7% |
| J Zhang et al | 209 | 13.58 | 2.26 | 252 | 13.28 | 1.09 | | 0.17 | [-0.01; (| 0.36] | 5.0% |
| Yu et al | 864 | 13.95 | 0.97 | 799 | 13.75 | 0.83 | | 0.22 | [0.12; 0 | 0.32] | 5.4% |
| White et al | 75 | 13.87 | 1.69 | 34 | 13.51 | 1.47 | | 0.22 | [-0.18; (| 0.631 | 3.6% |
| Jiac Liu et al | 79 | 11.44 | 1.48 | 43 | 11.13 | 1.14 | | 0.23 | [-0.14: (| 0.601 | 3.8% |
| NRCSC | 109 | 14.69 | 11.52 | 335 | 12.88 | 5.95 | | 0.23 | [0.02; 0 | 0.45] | 4.8% |
| Karakoyun et al | 84 | 12.89 | 1.34 | 113 | 12.56 | 1.27 | | 0.25 | [-0.03; (| 0.54] | 4.4% |
| Z Chen et al | 43 | 13.62 | 2.85 | 158 | 12.76 | 2.44 | | 0.34 | [0.00; 0 | 0.68] | 4.0% |
| Y Zhao et al | 74 | 12.34 | 0.98 | 211 | 12.04 | 0.82 | | 0.35 | [0.08; (| 0.61] | 4.5% |
| H Zhang et al | 14 | 10.63 | 0.57 | 29 | 10.41 | 0.46 | | 0.43 | [-0.21; | 1.08] | 2.3% |
| K Zheng et al | 28 | 12.50 | 1.20 | 52 | 12.00 | 1.00 | | 0.46 | [0.00; 0 | 0.93] | 3.2% |
| Gerotziafas et al (1) | 102 | 14.75 | 1.27 | 208 | 14.09 | 1.12 | | 0.56 | [0.32; (| 0.81] | 4.7% |
| Jiao Liu et al | 261 | 12.25 | 1.71 | 841 | 11.41 | 1.21 | | 0.62 | [0.48; (| 0.76] | 5.2% |
| Jie Liu et al | 152 | 12.67 | 1.25 | 62 | 11.90 | 1.20 | | 0.63 | [0.33; (| 0.93] | 4.3% |
| G Zhang et al | 55 | 13.62 | 1.91 | 166 | 12.78 | 0.97 | | 0.66 | 0.35; 0 | 0.971 | 4.2% |
| Liao et al | 231 | 15.46 | 4.50 | 149 | 13.10 | 0.90 | | 0.66 | [0.45; (| 0.871 | 4.9% |
| Bastug et al | 46 | 13.49 | 1.38 | 145 | 12.46 | 0.98 | | 0.94 | [0.60; | 1.29] | 4.0% |
| Dandam offects medal | 2835 | | | 4976 | | | - | 0.28 | [0.15; 0 | 0.42] | 100.0% |

- **Figure 4.** Forest plots of the association between COVID-19 severity and: (A) fibrinogen,
- 238 (B) activated partial thromboplastin time, (C) prothrombin time.

| | | Effect Size | • | | Heterogeneity | | | | |
|-----------|---------|--------------------|------|----------|---------------|-------------|----------|--|--|
| | Pooled | | | | | | | | |
| Parameter | r SMD | 95% CI | t | p value | I^2 (%) | tau-squared | p value | | |
| PLT | -0.1684 | [-0.2826; -0.0542] | -3 | 0.0051 | 82.2 | 0.0743 | < 0.0001 | | |
| DD | 0.6985 | [0.5155; 0.8815] | 7.74 | < 0.0001 | 94.2 | 0.2636 | < 0.0001 | | |
| FIB | 0.661 | [0.3387; 0.9833] | 4.27 | 0.0003 | 90.4 | 0.4812 | < 0.0001 | | |
| APTT | 0.2683 | [0.1357; 0.4009] | 4.22 | 0.0004 | 82.8 | 0.0558 | < 0.0001 | | |
| PT | 0.284 | [0.1472; 0.4208] | 4.3 | 0.0003 | 80 | 0.0785 | < 0.0001 | | |

239

Table 1. Summary of the effect sizes for all coagulation parameters

240

241 **3.3.2 Sensitivity and Subgroup Analysis**

Neither the analysis by the leave-one-out method nor the influence diagnostic has identified studies that solely cause a significant change in the effect size estimates. Removal of several outliers based on the pooled and individual confidence intervals allowed significant decrease in heterogeneity, yet it did not affect the interpretation of the results. Adjusted effect sizes and heterogeneity measurements are summarized in **Table 2**. All influence diagnostic plots, such as Baujat and leave-one-out plots, Cook's distance, Covariance Ratio, etc., are provided in the **Suppl. Figures 1-16** along with resulting Forest plots.

249 GOSH plots were built for all five models. K-means, DBSCAN, and Gaussian Mixture 250 Model were implemented as clustering methods. This diagnostic was not applied on PLT and 251 DD since they only have one cluster each (Figure 5); for FIB, APTT, and PT, on the other 252 hand, we constructed the plots and identified several possible influential cases. Original 253 GOSH plots for these parameters are given at Suppl. Figures. For fibrinogen, models that 254 include studies by Fu et al. (2020) and Wang et al. (2020) tend to show higher heterogeneity 255 and greater effect size (Figure 6A-B). For activated partial thromboplastin time, GOSH plot 256 demonstrated that studies by J. Zhao et al. (2021), H. Zhang et al (2020), and Yu et al. (2020) 257 increase model's heterogeneity and slightly pull the effect size to the left (Figure 6C-E).

GOSH plots of the prothrombin time effect size identified four studies, three of which (J. Zhao et al (2021), Cugno et al. (2021), and Zhou et al. (2021) pull effect size to the left (**Figure 6F-H**), and one (Bastug et al.) pulls effect size to the right (**Figure 6I**). We've excluded these studies and recalculated the pooled effect size for each parameter. Results are summarized in **Table 2**.

263 To explore the possible sources of heterogeneity and test the robustness of our data, we 264 have conducted subgroup analyses based on articles' country of origin and criteria for 265 severity stratification. Results are summarized in **Table 3**. Subgroup analysis showed no significant difference between articles originated from different countries but revealed that 266 267 severity assessment criteria might have an influence on overestimated effect sizes for PLT 268 and DD. High heterogeneity levels seem to be persistent oven different subgroups. Being the 269 only exception, values of APTT obtained from non-Chinese articles were less heterogenous -270 47.1% compared to 84.7% in studies originated in China.



Figure 5. GOSH diagnostic for influential cases in meta-analysis models (A) - PLT, (B) DD.



274

275 Figure 6. GOSH plots fixed for influential studies in meta-analysis models. (A-B) -

276 fibrinogen; (C-E) - APTT; (F-I) - prothrombin time.

277

Table 2. Summary results of the sensitivity analysis

| | | | | Heteroger | neity | | | |
|-------|--------------------|---------------|--------------------|-----------|----------|--------------------|-----------------|--------------------|
| Coagu | lation Parameter | Pooled SMD | 95% CI | t | p value | I ² (%) | tau- squared | Q test p- value |
| PLT | Original | -0.1684 | [-0.2826; -0.0542] | -3 | 0.0051 | 82.2 | 0.0743 | < 0.0001 |
| | Outliers removed | -0.1416 | [-0.2419; -0.0412] | -2.9 | 0.0076 | 56.3 | 0.0287 | 0.0002 |
| | Inf. Stud. removed | - | - | - | - | - | - | - |
| DD | Original | 0.6985 | [0.5155; 0.8815] | 7.74 | < 0.0001 | 94.2 | 0.2636 | < 0.0001 |
| | Outliers removed | 0.621 | [0.4860; 0.7560] | 9.47 | < 0.0001 | 70.2 | 0.073 | < 0.0001 |
| | Inf. Stud. removed | - | - | - | - | - | - | - |
| FIB | Original | 0.661 | [0.3387; 0.9833] | 4.27 | 0.0003 | 90.4 | 0.4812 | < 0.0001 |
| | Outliers removed | 0.5889 | [0.4141; 0.7638] | 7.14 | < 0.0001 | 85 | 0.0801 | < 0.0001 |
| | Inf. Stud. removed | 0.4855 | [0.3030; 0.6679] | 5.57 | < 0.0001 | 86.1 | 0.1175 | < 0.0001 |
| APTT | Original | 0.2683 | [0.1357; 0.4009] | 4.22 | 0.0004 | 82.8 | 0.0558 | < 0.0001 |
| | Outliers removed | 0.348 | [0.2450; 0.4518] | 7.14 | < 0.0001 | 38.6 | 0.0125 | 0.0532 |
| | Inf. Stud. removed | 0.3214 | [0.2036; 0.4392] | 5.73 | < 0.0001 | 68.8 | 0.0326 | < 0.0001 |
| PT | Original | 0.284 | [0.1472; 0.4208] | 4.3 | 0.0003 | 80 | 0.0785 | < 0.0001 |
| | Outliers removed | 0.293 | [0.2099; 0.3761] | 7.44 | < 0.0001 | 26.9 | 0.0064 | 0.1407 |
| | | | | | | | | |

|] | Inf. Stud. r | removed 0.283 | [0.1 | [336; 0.4325] | 3.94 0.000 | 8 81 | 0.0877 | < 0.0001 |
|-----------------|--------------|----------------|------|----------------|---------------|-------------|-----------------|----------------|
| | | | | Effect Size | | Heterog | eneity | |
| Coag. Param. | Variable | Subgroups | k | SMD [95%C] | [] | $I^{2}(\%)$ | tau- squared | p- subgroup |
| PLT | Location | | | | | | | 0.2123 |
| | | China | 19 | -0.2256 [-0.37 | 747; -0.0764] | 84.6 | 0.0694 | |
| | | Other | 15 | -0.1384 [-0.30 | 037; 0.0270] | 73.60% | 0.0765 | |
| | Criteria | | | | | | | 0.0263 |
| | | Guidelines | 19 | -0.1618 [-0.33 | 319; 0.0082] | 85.10 | 0.0983 | |
| | | ICU | 9 | -0.1188 [-0.30 |)56; 0.0680] | 70.60 | 0.0308 | |
| | | Aggravation | 3 | -0.0948 [-0.87 | 750; 0.6854] | 74.60 | 0.0682 | |
| | | Oxygen Therapy | 3 | -0.6834 [-1.43 | 303; 0.0636] | 0.00 | 0 | |
| DD | Location | | | | | | | 0.3596 |
| | | China | 23 | 0.7618 [0.508 | 9; 1.0148] | 94.70 | 0.3043 | |
| | | Other | 14 | 0.5992 [0.320 | 4; 0.8780] | 91.60 | 0.1964 | |
| | Criteria | | | | | | | 0.0041 |
| | | Guidelines | 22 | 0.6349 [0.424 | 48; 0.8450] | 92.10 | 0.1903 | |
| | | ICU | 12 | 0.9257 [0.50 | 07; 1.3506] | 96.70 | 0.4027 | |
| | | Aggravation | 3 | 0.2526 [-0.24 | 58; 0.7510] | 54.60 | 0.0182 | |
| FIB | Location | | | | | | | 0.0813 |
| | | China | 11 | 0.9393 [0.315 | 4; 1.5632] | 93.50 | 0.8093 | |
| | | Other | 11 | 0.4162 [0.175 | 7; 0.6567] | 74.50 | 0.0937 | |
| | Criteria | | | | | | | 0.156 |
| | | Guidelines | 13 | 0.8539 [0.312 | 8; 1.3949] | 92.60 | 0.7496 | |
| | | ICU | 8 | 0.4510 [0.169 | 0; 0.7330] | 84.30 | 0.0814 | |
| | | Aggravation | 1 | 0.3031 [0.025 | 3; 0.5809] | - | - | |
| APTT | Location | | | | | | | 0.8248 |
| | | China | 13 | 0.2768 [0.073 | 0; 0.4806] | 88.30 | 0.0872 | |
| | | Other | 8 | 0.2499 [0.066 | 61; 0.4337] | 47.10 | 0.0169 | |
| | Criteria | | | | | | | 0.359 |
| | | Guidelines | 16 | 0.2629 [0.10 | 19; 0.4240] | 84.70 | 0.0636 | |
| | | ICU | 4 | 0.3500 [-0.13 | 07; 0.8306] | 70.60 | 0.052 | |
| | | Aggravation | 1 | 0.0714 [-0.20 | 51; 0.3480] | - | - | |

283 **Table 3.** Summary results of the subgroup analysis

| РТ | Location | l | | | | | 0.9249 |
|----|----------|-------------|----|--------------------------|-------|--------|--------|
| | | China | 16 | 0.2886 [0.1188; 0.4584] | 81.80 | 0.0751 | |
| | | Other | 8 | 0.2745 [-0.0244; 0.5734] | 78.30 | 0.1016 | |
| | Criteria | | | | | | 0.6332 |
| | | Guidelines | 18 | 0.2889 [0.1401; 0.4377] | 79.00 | 0.0628 | |
| | | ICU | 5 | 0.2992 [-0.2853; 0.8836] | 87.6 | 0.1962 | |
| | | Aggravation | 1 | 0.1407 [-0.1360; 0.4175] | - | - | |

284

285 3.3.3 Publication Bias

286 Contour-enhanced funnel plots for five coagulation parameters are depicted in Figure 7, 287 and the results of Egger's test are summarized in **Table 4**. Based on the linear regression 288 results, significant asymmetry is observed in published studies that included results for PLT, 289 DD (Intercept [p-value]: -1.297 [0.0336], 3.182 [0.0013]), and somewhat significant 290 asymmetry was indicated for FIB (1.872 [0.0493]). While it is impossible to predict whether 291 asymmetry is coming solely from publication bias, contour-enhanced funnel plots for DD and 292 FIB (Figure 6B-C) show that the number of papers with insignificant findings is very small 293 (p > 0.1). This may advocate for the presence of some publication bias. In contrast, **Figure** 294 **6A** illustrates that even though the funnel plot for PLT has some asymmetry, there are plenty 295 of publications with insignificant SMDs, thus decreasing the possibility of publication bias.

To further explore the robustness of our findings, we have conducted several additional tests. As reported by Zwetsloot (2017) and his colleagues, plotting SMD against its standard error to assess the publication bias can result in distorted funnel plots, leading to falsepositive conclusions. Since SMD is necessary for our analysis and cannot be substituted, we used a sample size-based precision estimate instead of the standard error – $1/\sqrt{n}$. The resulting funnel plots (**Supplemental Figure 16**) showed no significant distortion.

Similar corrections were made to Egger's test: since standardized mean difference and
 standard error are not independent, we can expect the test to yield some false-positive results.

In our calculations, we used the corrected SE suggested by Pustejovsky and Rodgers (2019). Results are given in the **Supplemental Table 2.** The only model that was affected by this correction was FIB (intercept 2.142 with a p-value of 0.0526 compared to the initial 1.872 and 0.0493), indicating that previously concluded asymmetry might have been a false positive. Interpretation of results for other parameters remained the same.



309

Figure 7. Contour-enhanced funnel plots evaluating the presence of publication bias in the

311 pool of articles that report association between COVID-19 severity and (A) platelets; (B) D-

dimer; (C) fibrinogen; (D) activated partial thromboplastin time; (E) prothrombin time.

| Parameter | Intercept | Confidence Interval | t | p-value |
|-----------|-----------|---------------------|--------|---------|
| PLT | -1.297 | [-2.44, -0.15] | -2.221 | 0.0336 |
| DD | 3.182 | [1.39, 4.97] | 3.489 | 0.0013 |
| FIB | 1.872 | [0.12, 3.63] | 2.093 | 0.0493 |
| APTT | 0.775 | [-1.37, 2.92] | 0.708 | 0.4874 |
| PT | -0.436 | [-2.49, 1.62] | -0.417 | 0.6811 |

| 313 | Table 4. | Egger' | s test | for pu | blica | tion | bias |
|-----|----------|--------|--------|--------|-------|------|------|
|-----|----------|--------|--------|--------|-------|------|------|

314

315 **4. Discussion**

316 There is a need to identify early indicators of the risk of critical patients progressing to ICU at COVID-19. Abnormal coagulation parameters, including DD and FIB levels, changes 317 318 in PLT, and PT, are observed in many patients with COVID-19 infection at admission (rev. 319 Levi et al., 2020; Iba et al., 2020). However, as discussed by different authors, these 320 indicators provide contradictory information regarding risk stratification and prognosis (Luo 321 et al., 2020; Tang et al., 2020; Ding et al., 2021). There are several previous meta-analysis 322 reviews researching abnormal coagulation and the severity of COVID-2019 infection. The 323 majority of analyzed studies were conducted at the beginning of the pandemic and examined 324 the Chinese population of patients (before April 2020 - Xiong et al., 2020; Lippi et al., 2020; 325 Zhang et al., 2020; Zhu et al., 2021; June 2020 -Di Minno et al., 2020). Through our meta-326 analysis study, it was revealed that DD and FIB levels, APTC, and prothrombin time were 327 significantly higher in the severe group of COVID-19 patients. In contrast, PLT was 328 significantly lower in these patients. There was no evidence of effects across different 329 geographic subgroups, with the exception of APTT values.

330

331 4.1 Platelet changes

332 In this meta-analysis, we systematically analyze evidence for the utility of lowered PLT 333 levels on admission in the relationship to the severity of infection. Platelets play a crucial role 334 in the maintenance of hemostasis, contribute to thromboinflammatory processes (van der 335 Meijden, Heemskerk, 2019) and at different stages of viral infection, changes in platelet 336 production or destruction may result in coagulation imbalances leading to pro-thrombotic 337 events or in platelet disfunction and bleeding risks (Assinger, 2014), and increased activation 338 of platelets (Hottz et al., 2020; Zaid et al., 2020; Althaus et al., 2021). Thrombocytopenia (platelet count $<150 \times 10^{9}$ /L) seems to represent an important marker of COVID-19 severity 339 340 (Qu et al., 2020; Yang et al., 2020; Lippi et al., 2020; Iba et al., 2020) and mortality outcome 341 (Lippi et al., 2020; Yang et al., 2020). The reasons for a thrombocytopenia are multi-factorial, 342 which may include early suppression of megakaryocytes production and damage in bone 343 marrow and lungs, hemophagocytosis, immune destruction of platelets and other reasons. 344 Significant thrombocytopenia in COVID-19 is less frequent than it was reported for the 345 largest SARS-1 cohort (45%) (Lee et al., 2003). SARS-1 induced platelet depletion was 346 related to direct infection of megakaryocytes and hematopoietic progenitors (rev. by Yang et 347 al., 2005). However, almost half of patients presented thrombocytosis following initial 348 thrombocytopenia during SARS epidemics in 2003 (Wong et al., 2003). Recently, a different 349 trend in platelet changes in COVID-19 patients with immune thrombocytic purpura (ITP) was 350 reported by Cruz-Benito et al. (2021). Secondary to SARS-CoV2 infection in ITP-patients 351 generally develops early thrombocytosis (Cruz-Benito et al., 2020). Only a few cases of 352 thrombocytosis (in children) were reported during SARS-CoV2 pandemics (Feld et al., 2020) 353 as part of a multisystem inflammatory syndrome in children associated with COVID-19 354 (MIS-C) (Yasuhara et al., 2020). It is possible that opposite PLT changes may reflect 355 different phases of COVID-19 infection (Thachil et al., 2020) - acute and convalescent 22

356 phases, though the explanation has not been established yet. The reactive thrombocytosis that 357 may occur during the convalescent phase requires time observation that would include a 358 period preceding patient discharge. The increase of immature reticulated platelets reported 359 recently in COVID-19 patients by different groups (Cohen et al., 2021; Welder et al., 2021) 360 may play a role in the limiting of effectiveness of anti-platelet therapies (Guthikonda et al., 361 2007; Ibrahim et al., 2012; Armstrong et al., 2017). Change in platelets parameters (increased 362 mean volume) (Lippi et al., 2021) and reactivity are suggested to be associated with a severe 363 COVID-19 infection (Hottz et al., 2020; Yatim et al., 2021).

4.2 DD and FIB levels, and Thromboembolic complications

365 Concordant with other studies, we found DD and FIB levels significantly elevated in 366 severe COVID-19 infection, though DD levels results may suffer from some publication bias 367 as revealed by meta-regression analysis. It may be related to the variability of DD assays used 368 in the different studies: they are not directly comparable due to the difference in the 369 monoclonal antibodies used for tests (Olson et al., 2013; rev. Goodwin et al., 2017). As 370 confirmed by autopsy results, the elevated DD levels can be associated with fibrin deposits 371 within pulmonary extravascular space and alveoli (Fox et al., 2020), but they may be 372 nonspecific to intravascular fibrin formation (Hunt et al., 2020). High DD levels, together 373 with elevated neutrophils, were reported to be predictive factors of pulmonary embolism in 374 COVID-19 patients (Thoreu et al., 2021). Thromboembolic complications related to COVID-375 19 are responsible for a substantial mortality rate (Lodigiani et al., 2020; Kunutsor, 376 Laukannen, 2020; Piazza et al., 2020; Grillet et al., 2020). Whereas the highest burden of 377 thromboembolism is associated with patients in the ICU (Helms et al., 2020; Llitjos et al., 378 2020; Klok et al., 2020), patients in non-ICU settings also bear a significant risk of these 379 complications, especially VTE (venous thromboembolism) (Lodigiani et al., 2020; 380 Spyropoulos et al., 2020), as well as pulmonary embolism (Thoreau et al., 2021). Klock and 23

381 colleagues (2020) report that in spite of thrombosis prophylaxis, a high incidence of 382 thrombotic complications in ICU patients is comparable with patients from other groups with 383 DIC (disseminated intravascular coagulation). Moreover, multiple studies describe cerebral 384 venous thrombosis (CVT) associated with COVID-19 infection (Garaci et al., 2020; Baudar 385 et al., 2020). DD and FIB levels are elevated in COVID-19 and in thromboembolism, and 386 therefore as single tests are unspecific and unhelpful in the differentiation of these conditions. 387 In part, it may be explained by the involvement in abnormal coagulation at COVID-19 of 388 different systems, including endothelial cells, complement activation, and hypofibrinolysis 389 resulting in changes undetected by routine tests (Holter et al., 2020; Cugno et al., 2021). The 390 dysfunction of endothelial cells with COVID-19 may contribute to excess thrombin 391 generation and fibrinolysis shutdown, which is associated with VTE, stroke and, renal failure 392 (Wright et al., 2020). There are different suggestions for COVID-19 risk stratification related 393 to changes in platelets and endothelial cells, such as increased proportion of immature 394 reticulated platelet fraction (Cohen et al., 2021; Welder et al., 2021) or CECs (circulating 395 endothelial cells) counts in the blood representing stressed cells detached from injured 396 vessels, reported in various inflammatory and infective diseases, and are indicative of disease 397 severity (Blann et al., 2006). They were significantly higher in COVID-19 patients admitted 398 to the ICU and positively correlated with the length of hospital stay (Guervilly et al., 2020). 399 This marker is related to SARS-CoV2 directly infecting primary endothelial cells (Monteil et 400 al., 2020). Furthermore, there is some evidence of infection in endothelial cells in severe 401 cases of COVID-19 (Varga et al., 2020), including the presence of coronavirus particles in 402 the cytoplasm of endothelial cells on electron microscopy (Colmenero et al., 2020). Platelets 403 activation and endothelial cell damage in COVID-19 patients are also resulting in elevated 404 levels of extracellular vesicles (EVs) (Capellano et al., 2021) recently associated with 405 severity of disease (Krishnamachary et al., 2021).

406 4.3 Fibrinolysis shutdown requires evaluation outside conventional coagulation 407 parameters

408 Fibrinolysis shutdown is induced by severe COVID-19 infection (Tang et al., 2020; 409 Wright et al., 2020; Collett et al., 2021) and is partly responsible for high DD and FIB levels. 410 Some pathophysiological changes may contribute to high procoagulant conditions secondary 411 to COVID-19 infection. Thus, low plasminogen levels (Correa et al., 2020), similar to 412 plasminogen-related fibrinolysis observed at other viral infections such as influenza infection 413 (Berri et al., 2013), may lead to a hypercoagulability state. A multiplexed analysis of 414 inflammation-related gene expression (249 genes from nCounter Inflammation panel; 415 NanoString Technologies, USA) revealed similarities between lung specimens in influenza 416 and Covid-19 groups (Ackermann et al., 2020). Depression of fibrinolysis was reported not 417 only in ICU patients with severe infection and clinical signs of thromboembolism (Wright et 418 al., 2020), but also in the general unselected ICU cohort (Correa et al., 2020; Collett et al., 419 2020; Nougier et al., 2020). Viscoelastic testing (ROTEM, tissue-type plasminogen activator 420 (tPA) ROTEM, TEG) and evaluation of clot formation by Clot Waveworm analysis have 421 demonstrated a hypercoagulable state, characterized by increased clot stiffness and severely 422 impaired fibrinolysis (Nougier et al., 2020; Collett et al., 2020; Panigada et al., 2020; Pavoni 423 et al., 2020; Fan et al., 2021; Hulshof et al., 2021). Elevated routine coagulation parameters 424 taken at admission may help with initial differentiation of severe and non-severe COVID-19 425 patient groups, but they do not provide information about fibrinolysis shutdown.

Although our findings were consistent across different geographic groups, they were tempered by significant heterogeneity. The DD, FIB, and PLT elevation trends speak about the necessity of investigating the potential of additional specific biomarkers for stratification of COVID-19 patients at risk for fibrinolytic shutdown and associated micro-and macrovascular events. We suggest that thorough characterization of platelets including a proportion 25

of immature reticulated platelets and their size/mean volume parameters as well as a clot
formation testing requires to evaluate a risk of thromboembolic events in COVID-19 patients
groups.

434 **5 Limitations of the study**

435 Our findings should be interpreted with some limitations. Firstly, most of the included 436 studies were either retrospective and observational by design, thus prone to recall or 437 misclassification bias. Second, such studies often imply recruitment by convenience 438 sampling, in which case the representativeness of a study is questioned. The random effects 439 model was used due to the high heterogeneity of research. In the context of this meta-440 analysis, several different endpoints were allowed: severity guidelines, ICU admissions, 441 oxygen therapy requirement, and disease aggravation. In an attempt to overcome this issue, 442 we have conducted a subgroup analysis. Third, uncontrolled variables might also pose a 443 limitation - both the disease severity and coagulation parameters can be affected by several 444 potential confounding variables, such as comorbidities, age, etc. Some studies have reported 445 their results in terms of quartiles or maximum and minimum values. The necessity to convert 446 values could potentially influence the results. Although sensitivity and subgroup analyses 447 were conducted, some residual heterogeneity may affect the interpretation of results. Finally, the underlying mechanisms of coagulation markers at COVID-19 still need to be 448 449 investigated.

450 **6 Conclusions**

Our findings support using a combination of coagulation parameters for risk stratification of patients with COVID-19 infection at the time of admission. However, additional evaluation using clotting formation methods or combination with platelet-specific biomarkers requires. This information may help physicians triage patients with thromboembolism. An

important consideration is an intermediate and long follow-up of COVID-19 patients. We
hypothesize that increase in platelets turnover towards immature reticulated forms contribute
to hypercoagulability state at COVID-19 patients and their resistance to anti-platelet therapy.
Future research should take in account change in platelet parameters and platelet
fragmentation leading to elevated levels of extracellular vesicles.

460 **7 Data availability Statement**

461 Data are available by request from co-corresponding authors.

462 **8 Conflict of Interest**

463 The authors declare no conflict of interest.

464 **9 Author Contributions**

465 P.L. - conceptualization, methodology, formal analysis, investigation, data curation, writing

466 original draft, G.I., Z.S., A.K. – methodology, data curation, formal analysis, investigation;

467 A.T.T., M.M.S., A.S.D., M.M.A., M.S.B. - methodology, formal analysis, investigation, data

468 curation of NRCSC cohort, writing a draft; E.D.P., A.T.- methodology; analysis; funding,

469 N.S.B. - conceptualisation, methodology, formal analysis, investigation, data curation,

470 writing a draft. M.S.B. and N.S.B.- supervision. All authors read and edit a final draft.

471 **10 Acknowledgments**

475

We are very grateful to Sadyk Khamitov and Aliya Sailybayeva from the Research Department of National Research Center for Cardiac Surgery for their excellent organizational help. N.S.B. and A.T. were supported by FDCRGP SSH2020028, and N.S.B.

by OPCRP2020018 grants from Nazarbayev University.

476 **11 Abbreviations**

| 477 | APTT - activated partial thromboplastin time; CI - confidence interval; DD - D-dimer; DIC - |
|-----|---|
| 478 | disseminated intravascular coagulation; FIB - fibrinogen; GOSH - graphical display of study |
| 479 | heterogeneity; ICU - intensive care unit; MERS-CoV - Middle East respiratory syndrome |
| 480 | coronavirus (MERS-CoV); NRCSC - National Research Center for Cardiac Surgery; PLT - |
| 481 | platelets; PT - prothrombin time; ROTEM - rotation thromboelastometry; SARS-CoV - |
| 482 | severe respiratory acute syndrome coronavirus (SARS-CoV); SMD - standardized mean |
| 483 | difference; tPA - tissue-type plasminogen activator; VTE - venous thromboembolism; vWF |
| 484 | - von Willebrand factor. |

485

486 12 References

- 487 Ackermann, M., Verleden, S.E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., et al.
- 488 (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N.

489 Engl. J. Med. 383, 120-128. doi: 10.1056/NEJMoa2015432

- 490 Aloisio, E., Chibireva, M., Serafini, L., Pasqualetti, S.S.F., Dolci, A., Panteghini, M., et al.
- 491 (2020). A comprehensive appraisal of laboratory biochemistry tests as major predictors of
- 492 COVID-19 severity. Arch. Pathol. Lab. Med. 144, 1457-1464. doi: 10.5858/arpa.2020-0389493 sa
- 494 Althaus, K., Marini, I., Zlamal, J., Pelzl, L., Singh, A., Häberle, H., et al. (2021). Antibody-
- induced procoagulant platelets in severe COVID-19 infection. Blood. 137, 1061–1071. doi:
 10.1182/blood.2020008762
- Armstrong, P.C., Hoefer, T., Knowles, R.B., Tucker, A.T., Hayman, M.A. et al. (2017)
 Newly formed reticulated platelets undertmine pharmacokinetically short-lived antiplatelet

- 499 therapies. Atherosclerosis, Thromb. Vascular Biol. 37, 949-956.
- 500 doi.org/10.1161/ATVBAHA.116.308763
- 501 Assinger, A. (2014). Platelets and infection-an emerging role of platelets in viral infection.
- 502 Front. Immunol. 5, 649. doi: 10.3389/fimmu.2014.00649
- 503 Bastug, A., Bodur, H., Erdogan, S., Gokcinar, D., Kazancioglu, S., Deniz, B., et al. (2020).
- 504 Clinical and laboratory features of COVID-19: predictors of severe prognosis. Int.
- 505 Immunopharmacol. 88:106950. doi: 10.1016/j.intimp.2020.106950
- 506 Baudar, C., Duprez, T., Kassab, A., Miller, N., Rutgers, M.P. (2020). COVID-19 as
- 507 triggering co-factor for cortical cerebral venous thrombosis? J Neuroradiol. 2020, 30205-
- 508 302144. doi: 10.1016/j.neurad.2020.06.008
- 509 Bauer, W., Galtung, N., Neuwinger, N., Kaufner, L., Langer, E., Somasundaram, R., et al.
- 510 (2021). A matter of caution: coagulation parameters in COVID-19 do not differ from patients
- 511 with ruled-out SARS-CoV-2 infection in the emergency department. TH Open. 5, e43-e55.
- 512 doi: 10.1055/s-0040-1722612
- 513 Becker, R.C., Sexton, C., Smyth, S. (2021). COVID-19 and biomarkers of thrombosis: focus
- on von Willebrand factor and extracellular vesicles. J. Thromb. Thrombolysis. 1-10. doi:
 10.1007/s11239-021-02544-x
- 516 Bergantini, L., Bargagli, E., d'Alessandro, M., Refini, R., Cameli, P., Galasso, L., et al.
- 517 (2021). Prognostic bioindicators in severe COVID-19 patients. Cytokine. 141, 155455. doi:
- 518 10.1016/j.cyto.2021.155455
- Berri, F., Rimmelzwaan, G.F., Hanss, M., Albina, E., Foucault-Grunenwald, M.L., Le, V.B.,
 et al. (2013). Plasminogen controls inflammation and pathogenesis of influenza virus
 infections via fibrinolysis. PLoS Pathog. 9, e1003229. doi: 10.1371/journal.ppat.1003229

- 522 Blann, A.D., Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., et al.
- 523 (2005). Circulating endothelial cells. Thromb. Haemost. 93, 228-235. doi: 10.1160/TH04-09524 0578
- 525 Cappellano, G., Raineri, D., Rolla, R., Giordano, M., Puricelli. C., Vilardo, B., et al. (2021)
- 526 Circulating platelet-derived extracellular vesicles are a hallmark of SARS-Cov-2 infection.
- 527 Cells 10, 85. 10.3390/cells10010085
- 528 Cen, Y., Chen, X., Shen, Y., Zhang, X., Lei, Y., Xu, C., et al. (2020). Risk factors for disease
- 529 progression in patients with mild to moderate coronavirus disease 2019 a multi-centre
- 530 observational study. Clin. Microbiol. Infect. 26, 1242-1247. doi: 10.1016/j.cmi.2020.05.04
- 531 Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020). Epidemiological and
- 532 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
- 533 descriptive study. Lancet. 395, 507-513. doi: 10.1016/S0140-6736(20)30211-7
- Chen, N., Li, Y., Fan, H., Tian, A., Yuan, H., Jiang, Z., et al. (2020). Analysis of dynamic
 disturbance in blood coagulation function of patients with coronavirus disease 2019: a
 retrospective observational study. Medicine. 99, e22635. doi: 510
 10.1097/MD.00000000022635
- Chen, Q., Zheng, Z., Zhang, C., Zhang, X., Wu, H., Wang, J., et al. (2020). Clinical
 characteristics of 145 patients with coronavirus disease 2019 (COVID-19) in Taizhou,
 Zhejiang, China. Infection. 48, 543–551. doi: 10.1007/s15010-020-01432-5
- Chen, Z., Zhang, F., Hu, W., Chen, Q., Li, C., Wu, L., et al. (2021). Laboratory markers
 associated with COVID-19 progression in patients with or without comorbidity: A
 retrospective Study. J. Clin. Lab. Anal. 35, e23644. doi: 10.1002/jcla.23644

- 544 Cohen, A., Harari, E., Cipok, M., Laish-Farkash, A., Bryk, G., Yahud, E. et al. (2021).
- 545 Immature platelets in patients hospitalized with COVID-19. J. Thromb. Thrombolysis 51,
- 546 608-616. doi.org/10.1007/s11239-020-02290-6
- 547 Collett, L.W., Gluck, S., Strickland, R.M., Reddi, B.J. (2021). Evaluation of coagulation
- 548 status using viscoelastic testing in intensive care patients with coronavirus disease 2019
- 549 (Covid-2019): an observational point prevalence cohort study. Austr. Crit. Care. 34, 155-159.
- 550 doi: 10.1016/j.aucc.2020.07.003
- 551 Colmenero, I., Santonja, C., Alonso-Riano, M., Hernandez-Martin, A., Andina, D., Wiesner,
- 552 T., et al. (2020). SARS-CoV2 endothelial infection causes COVID-19 chilblains:
- 553 histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.
- 554 Br. J. Dermatol. 183, 729-737. doi: 10.1111/bjd.19327
- 555 Correa, T.D., Cordioli, R.L., Guerra, J.C.C., da Silva, B.C., Rodrigues, R.R., de Souza, G.M.,
- et al. (2020). Coagulation profile of COVID-19 patients admitted to the ICU: exploratory
- 557 study. PLoS ONE. 15, e0243604. doi: 10.1371/journal.pone.0243604
- 558 Creel-Bulos, C., Auld, S.C., Caridi-Scheible, M., Barker, N.A., Friend, S., Gaddh, M., et al.
- 559 (2021). Fibrinolysis shutdown and a thrombosis in a COVID-19 ICU. Shock. 55, 316-320.
- 560 doi: 530 10.1097/SHK.00000000000163
- 561 Cruz-Benito, B., Rivas-Pollmar, M.I., Roman, M.T.A., Trelles-Martinez, R., Martin-Salces,
- 562 532 M., Lazaro-del Campo, P. et al. (2020). Paradoxical effect of SARS-CoV2 infection with
- 563 immune thrombocytopenia. Br. J. Haematol. 192, 973-977. doi: 10.1111/bjh.17077
- 564 Cugno, M., Meroni, P. L., Gualtierotti, R., Griffini, S., Grovetti, E., Torri, A., et al. (2021).
- 565 Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
- 566 J. Autoimmun. 116, 102560. doi: 10.1016/j.jaut.2020.102560

- 567 Demelo-Rodriguez, P., Cervilla-Munoz, E., Ordieres-Ortega, L., Parra-Virto, A., Toledano-
- 568 Macias, M. et al. (2020). Influence of asymptomatic deep vein thrombosis in patients with
- 569 COVID-19 pneumonia and elevated D-dimers levels. Thrombosis Res. 192, 23-26. doi:
- 570 10.1016/j.thromres.2020.05.018
- 571 Di Micco, P., Russo, V., Carannante, N., Imparato, M., Cardillo, G., and Lodigiani, C.
- 572 (2020). Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency
- department: an Italian cohort study. J. Clin. Med. 9, 4134. doi: 10.3390/jcm9124134
- 574 Di Minno, M.N.D., Calcaterra, I., Lupoli, R., Storino, A., Spedicato, G.A., Maniscalco, M. et
- al. (2020) Hemostatic changes in patients with COVID-19: a meta-analysis with meta-
- 576 regressions. J. Clin. Med. 9, 2244; doi:10.3390/jcm9072244
- 577 Ding, R., Yang, Z., Huang, D., Wang, Y., Li, X., Zhou, X., et al. (2021). Identification of
- 578 parameters in routine blood and coagulation tests related to the severity of COVID-19. Int. J.
- 579 Med. Sci. 18, 1207–1215. doi: 10.7150/ijms.47494
- 580 Doevelaar, A. A., Bachmann, M., Hölzer, B., Seibert, F. S., Rohn, B. J., Bauer, F., et al.
- (2021). Von Willebrand factor multimer formation contributes to immunothrombosis in
 Coronavirus disease 2019. Critical Care Med. 49, e512-e520. doi:
 10.1097/CCM.00000000004918
- 584 Fan, B. E., Ng, J., Chan, S.S.W., Christopher, D., Tso, A.C.E., Ling, A.M. et al. (2021).
- 585 COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state
- 586 demonstrated by parameters of haemostasis and clot waveform analysis. J. Thromb.
- 587 Thrombolysis 51, 663-674. doi.org/10.1007/s11239-020-02318-x

- 588 Feld, L., Belfer, J., Kabra, R., Goenka, P., Rai, S., Moriarty, S., et al. (2020). A case series of
- the 2019 novel coronavirus (SARS-CoV-2) in 3 febrile infants in New York. Pediatrics.146,
- e20201056. doi: 10.1542/peds.2020-1056
- 591 Fox, S.E., Akmatbekov, A., Harbert, J.L., Li, G., Brown, J.Q., and Vander Heide, R.S.
- 592 (2020). Pulmonary and cardiac pathology in African American patients with COVID-19: an
- autopsy series from New Orleans. Lancet Respir. Med. 8, 681–686. doi: 10.1016/S2213-
- 594 2600(20)30243-5
- 595 Fu, J., Kong, J., Wang, W., Wu, M., Yao, L., Wang, Z., et al. (2020). The Clinical 596 implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a 597 retrospective study in Suzhou China. Thromb. Res. 192, 3-8. doi: 598 10.1016/j.thromres.2020.05.006
- Garaci, F., Di Giuliano, F., Picchi, E., Da Ros, V., and Floris, R. (2020). Venous cerebral
 thrombosis in COVID-19 patient. J. Neurol. Sci. 414, 116871. doi:
 10.1016/j.jns.2020.116871
- 602 Gerotziafas, G. T., Sergentanis, T. N., Voiriot, G., Lassel, L., Papageorgiou, C., Elabbadi, A.,
- et al. (2020). Derivation and validation of a predictive score for disease worsening in patients
- 604 with COVID-19. Thromb. Haemost. 120, 1680-1690. doi: 10.1055/s-0040-1716544
- 605 Giannis, D., Ziogas, I.A., and Gianni, P. (2020). Coagulation disorders in coronavirus
- 606 infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin.
- 607 Virol. 127, 104362. doi: 10.1016/j.jcv.2020.104362
- 608 Goeijenbier, M., Van Wissen, M., Van De Weg, C., Jong, E., Gerdes, V. E. A., Meijers, J. C.
- 609 M., et al. (2012). Review: viral infections and mechanisms of thrombosis and bleeding. J.
- 610 Med. Virol. 84, 1680-1696. doi: 10.1002/jmv.23354

- 611 Goodwin, A.J., Higgins, R.A., Moser, K.A., Smock, K.J., Chandler, V.L., Kottke-Marchant,
- 612 K., et al. (2017). Issues surrounding age-adjusted D-dimer cutoffs that practicing physicians
- 613 need to know when evaluating patients with suspected pulmonary embolism. Ann. Intern.
- 614 Med. 166, 361–364. doi: 10.7326/M16-2030
- Goshua, G., Pine, A.B., Meizlish, M.L., Chang, C.-H., Zhang, H., Bahel, P. et al (2020).
- 616 Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre,
- 617 cross-sectional study. Lancet Haematol. 7, e575–e582. doi: 10.1016/S2352 3026(20)30216-7
- Grillet, F., Behr, J., Calame, P., Aubry, S., and Delabrousse, E. (2020). Acute pulmonary
- 619 embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography.
- 620 Radiology. 23, 201544. doi: 10.1148/radiol.2020201544
- 621 Guervilly, C., Burtey, S., Sabatier, F., Cauchois, R., Lano, G., Abdili, E., et al. (2020).
- 622 Circulating endothelial cells as a marker of endothelial injury in severe COVID-19. J. Infect.
- 623 Dis. 222, 1789-1793. doi: 10.1093/infdis/jiaa528
- 624 Guthikonda, S., Lev, E.I., Patel, R., DeLao, T., Bergeron, A.L., Dong, J.F., et al. (2007)
- 625 Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of
- 626 aspirin. J. Thromb. Haemost. 5, 490-496. doi:10.1111/j.1538-7836.2007.02387.x
- Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., et al.
- 628 (2020). High risk of thrombosis in patients with severe SARS-CoV2-infection: a multicenter
- 629 prospective cohort study. Intens. Care Med. 46, 1089-1098. doi: 10.1007/s00134-020-06062-
- 630 X
- 631 Higuera-de-la-Tijera, F., Servín-Caamaño, A., Reyes-Herrera, D., Flores-López, A., Robiou
- 632 Vivero, E., Martínez-Rivera, F., et al. (2021). The Age-AST-D Dimer (AAD) regression

633 model predicts severe COVID-19 disease. Dis. Markers. 2021:6658270. doi:
634 10.1155/2021/6658270

- Holter, J.C., Pischke, S.E., de Boer, E., Lind, A., Jenum, S., Holten, A.R. et al. (2020).
- 636 Systemic complement activation is associated with respiratory failure in COVID-19 patients.
- 637 Proc. Natl. Acad. USA 117, 25018-25025
- 638 Hottz, E.D., Azevedo-Quintanilha, I.G., Palhinha, L., Teixeira, L., Barretto, E.A., Pao,
- 639 C.R.R. et al. (2020). Platelet activation and platelet-monocyte aggregate formation trigger
- 640 tissue factor expression in patients with severe COVID-19. Blood 136, 1330-1341.
- 641 https://doi.org/10.1182/blood.2020007252
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of
- patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 10223. doi:
 10.1016/s0140-6736(20)30183-5
- Hulshof, A.-M., Brueggemann, R.A.G., Mulder, M.M.G., van de Berg, T.W., Sels, J.-W.
- 646 E.M., Olie, R.H. (2021) Serial EXTEM, FIBTEM, and tPA Rotational thromboelastometry
- 647 observations in the Maastricht Intensive Care COVID Cohort persistence of
- 648 hypercoagulability and hypofibrinolysis despite anticoagulation. Front. Cardiovasc. Med. 8,
- 649 654174. doi: 10.3389/fcvm.2021.654174
- Hunt, B.J., Levi, M. (2020). The source of elevated plasma D-dimer levels in COVID-19
 infection. Br. J. Haematol. doi: 10.1111/bjh.16907
- Hwang, D. M., Chamberlain, D. W., Poutanen, S. M., Low, D. E., Asa, S. L., and Butany, J.
- 653 (2005). Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern.
- 654 Pathol. 18, 1–10. doi: 10.1038/modpathol.3800247

| 655 | Iba, T., Levy, | J.H., Levi, M., | Connors, | J.M., and | Thachil, | J. (202 | 0). Coagulopath | iy of |
|-----|----------------|------------------|----------|-----------|----------|---------|-----------------|-------|
| 656 | coronavirus | disease-2019. | Crit. | Care. | Med. | 48, | 1358-1364. | doi: |
| 657 | 10.1097/CCM.(| 0000000000000445 | 58 | | | | | |

- Ibrahim, H., Nadipalli, S., DeLao, T., Guthikonda, S., Kleiman, N.S. (2012) Immature
- 659 platelet fraction (IPF) determined with an automated method predicts clopidogrel
- 660 hyporesponsiveness. J. Thromb. Thrombolysis 33, 137–42. doi:10.1007/s11239-011-0665-7.
- 661 Johns Hopkins University & Medicine (2021). The Johns Hopkins Coronavirus Resource
- 662 Center (CRC). https://coronavirus.jhu.edu/ [Accessed September 30, 2021].
- Karakoyun, I., Colak, A., Turken, M., Altin, Z., Arslan, F. D., Iyilikci, V., et al. (2021).
- 664 Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in
- hospitalized severe COVID-19 patients. Int. Immunopharmacol. 91, 107285. doi:
 10.1016/j.intimp.2020.107285
- 667 Klok, F.A., Kruip, M.J.H.A., Van der Meer, N.J.M., Arbous, M.C., Gommers, D.A.M.P.J. et
- al. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-
- 669 19. Thrombosis Res. 191, 145-147. doi: 10.1016/j.thromres.2020.04.013
- 670 Krishnamachary, B., Cook, S., Kumar, A., Spikes, L., Chalise, P., Dhillon, N.K. (2021)
- 671 Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate
- with COVID-19 disease severity. J. Extracel. Vesicles. 10, e12117. doi: 10.1002/jev2.12117
- 673 Kunutsor, S.K., and Laukkanen, J.A. (2020). Incidence of venous and arterial
- 674 thromboembolic complications in COVID-19: a systematic review and meta-analysis.
- 675 Thrombosis Res. 196, 27-30. doi: 10.1016/j.thromres.2020.08.022

- Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G.M., et al. (2003). A major outbreak
- of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986–94.
 https://doi.org/10.1056/NEJMoa030685
- 679 Levi, M., and Scully, M. (2018). How I treat disseminated intravascular coagulation. Blood.
- 680 131, 845-854. doi: 10.1182/blood-2017-10-804096
- Levi, M., Thachil, J., Iba, T., Levi, J.H. (2020). Coagulation abnormalities and thrombosis in
 patients with COVID-19. Lancet Haematol. 7, e438-440. doi: 10.1016/ S23523026(20)30145-9
- Liao, D., Zhou, F., Luo, L., Xu, M., Wang, H., Xia, J., et al. (2020). Haematological
- characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a
- retrospective cohort study. Lancet Haematol. 7, e671-e678. doi: 10.1016/s23523026(20)30217-9
- Lippi, G., Plebani, M., and Henry, B.M. (2020). Thrombocytopenia is associated with severe
- 689 coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta 506,
- 690 145–148. doi:10.1016/j. cca.2020.03.022
- 691 Lippi, G., Henry, B.M., Favaloro, E.J. (2021). Mean platelet volume predicts severe COVID-
- 692
 19
 illness.
 Semin.
 Thromb.
 Hemost.
 47,
 456-459

 693
 DOI: 10.1055/s-0041-1727283
- Liu, J., Liu, Z., Jiang, W., Wang, J., Zhu, M., Song, J., et al. (2020a). Clinical predictors of
- 695 COVID-19 disease progression and death: analysis of 214 hospitalized patients from Wuhan,
- 696 China. Clin. Res. J. 15, 293-309. doi: 10.1111/crj.13296

- Liu, J., Zhang, S., Wu, Z., Shang, Y., Dong, X., Li, G., et al. (2020b). Clinical outcomes of
- 698 COVID-19 in Wuhan, China: a large cohort study. Ann. Intensive Care. 10, 1-21. doi:
- 699 10.1186/s13613-020-00706-3
- Liu, J., Tu, C., Zhu, M., Wang, J., Yang, C., Liu, W., and Xiong, B. (2021). The Clinical
- course and prognostic factors of severe COVID-19 in Wuhan, China. Medicine. 100: e23996.
- 702 doi: 10.1097/md.00000000023996
- 703 Liu, W., Tao, Z. W., Wang, L., Yuan, M. L., Liu, K., Zhou, L., et al. (2020). Analysis of
- factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus

705 disease. Chin. Med. J. 133, 1032–1038. doi: 10.1097/cm9.00000000000775

- Llitjos, J.-F., Leclerc, M., Chochois, C., Monsallier, J.-M., Ramakers, M., Auvray, M., et al.
- 707 (2020). High incidence of venous thromboembolic events in anticoagulated severe COVID-

708 19 patients. J. Thromb. Haemost. 18, 1743-1746. doi: 10.1111/jth.14869

- Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T.,
 et al. (2020). Venous and arterial thromboembolic complications in COVID 19 patients
 admitted to an academic hospital in Milan, Italy. Thromb. Res. 191, 9–14. doi:
 10.1016/j.thromres.2020.04.024
- 713 Long, H., Nie, L., Xiang, X., Li, H., Zhang, X., Fu, X., et al. (2020). D-Dimer and
- 714 prothrombin time are the significant indicators of severe COVID-19 and poor prognosis.
- 715 Biomed. Res. Int. 2020, 6159720. doi: 10.1155/2020/6159720
- 716 Lopez-Castaneda, S., García-Larragoiti, N., Cano-Mendez, A., Blancas-Ayala, K., Damian-
- 717 Vázquez, G., Perez-Medina, A. I., et al. (2021). Inflammatory and prothrombotic biomarkers
- associated with the severity of COVID-19 infection. Clin. Appl. Thromb. Hemost. 27, 1-9.
- 719 doi: 10.1177/1076029621999099

- Luo, D., Wan, X., Liu, J., and Tong, T. (2018). Optimally estimating the sample mean from
- the sample size, median, mid-range, and/or mid-quartile range. Stat. Meth. Med. Res. 27,
- 722 1785–1805. doi: 10.1177/0962280216669183
- Luo, L., Xu, M., Du, M., Kou, H., Liao, D., Cheng, Z., et al. (2020). Early coagulation tests
- 724 predict risk stratification and prognosis of COVID-19. Aging (Albany NY). 12, 15918-
- 725 15937. doi: 10.18632/aging.103581
- 726 Mikami, T., Miyashita, H., Yamada, T., Harrington, M., Steinberg, D., Dunn, A., and Siau, E.
- 727 (2021). Risk factors for mortality in patients with COVID-19 in New York City. J. Gen.
- 728 Intern. Med. 36, 17-26. doi: 10.1007/s11606-020-05983-z
- 729 Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., et al. (2020).
- 730 Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade
- 731 soluble human ACE2. Cell 181, 905-913. doi: 10.1016/j.cell.2020.04.004
- National Heart, Lung, and Blood Institute. (2019). Study quality assessment tools.
 https://www. nhlbi. nih. gov/health-topics/study-quality-assessment-tools [Accessed
 September 20th, 2021].
- Noh, C. S., Kim, W. Y., and Baek, M. S. (2021). Risk factors associated with the need for
 oxygen therapy in patients with COVID-19. Medicine. 100, e25819. doi:
 10.1097/md.00000000025819
- Nougier, C., Benoit, R., Simon, M., Desmurs-Clavel, H., Marcotte, G., Argaud. L., et al.
- 739 (2020) Hypofibrinolytic state and high thrombin generation may play a major role in SARS-
- 740 Cov2 associated thrombosis. J. Thromb. Haemost. 18, 2215-2219. doi: 10.1111/jth.15016

| 741 | Olson, J | .D., Cu | nninghar | n, M.T., Higg | gins, R.A | , Eby, C. | S., and I | Brandt, J | .T. (201 | 3). D-dimer: |
|-----|----------|---------|-----------|---------------|-----------|-----------|-----------|-----------|----------|--------------|
| 742 | simple | test, | tough | problems. | Arch. | Pathol. | Lab. | Med. | 137, | 1030-1038. |
| 743 | doi:10.5 | 858/arp | oa.2012-0 | 296-CP | | | | | | |

- Panigada, M., Bottino, N., Tagliabue, P., Grasselli, G., Novembrino, C., Chantarangkul, V.,
- et al. (2020). Hypercoagulability of COVID-19 patients in intensive care unit: a report of
- thromboelastograpgy and other parameters of hemostasis. J. Thromb. Haemost. 18, 1738-
- 747 1742. doi: 10.1111/jth.14850
- 748 Pavoni, V., Gianesello, L., Pazzi, M., Stera, C., Meconi, T., Frigieri, F.C. (2020) Evaluation

of coagulation function by rotation thromboelastometry in critically ill patients with severe

- COVID-19 pneumonia. J. Thromb. Thrombolysis. 50, 281-286. doi: 10.1007/s11239-02002130-7
- 752 Piazza, G., Campia, U., Hurwitz, S., Snyder, J. E., Rizzo, S. M., Pfeferman, M. B., et al.
- 753 (2020). Registry of arterial and venous thromboembolic complications in patients with
- 754 COVID-19. J. Am. Coll. Cardiol. 76, 2060-2072. doi: 10.1016/j.jacc.2020.08.070
- 755 Pustejovsky, M.A., and Rodgers, J.E. (2019). Testing for funnel plot asymmetry of
- standardized mean differences. Res. Synthesis Meth. 10, 57-71. doi: 10.1002/jrsm.1332
- 757 Qu, R., Ling, Y., Zhang, Y.H.Z., Wei, L.Y., Chen, X., Li, X.M. et al. (2020). Platelet-to
- lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J. Med.
- 759 Virol. 92, 1533-1541. doi: 10.1002/jmv.25767
- Ranucci, M., Ballotta, A., Di Dedda, U., Bayshnikova, E., Dei Poli, M., Resta, M., et al.
- 761 (2020). The procoagulant pattern of patients with COVID-19 acute distress syndrome. J.
- 762 Thromb. Haemost. 18, 1747-1751. doi: 10.1111/jth.14854

- Rauch, A., Labreuche, J., Lassalle, F., Goutay, J., Caplan, M., Charbonnier, L., et al. (2020).
- 764 Coagulation biomarkers are independent predictors of increased oxygen requirements in
- 765 COVID-19. J. Thromb. Haemost. 18, 2942-2953. doi: 10.1111/jth.15067
- Shang, W., Dong, J., Ren, Y., Tian, M., Li, W., Hu, J., et al. (2020). The value of clinical
- parameters in predicting the severity of COVID-19. J. Med. Virol. 92, 2188-2192. doi:
- 768 10.1002/jmv.26031
- 769 Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., et al. (2020).
- 770 Scientific and standardization committee communication: clinical guidance on the diagnosis,
- 771 prevention and treatment of venous thromboembolism in hospitalized patients with COVID-
- 772 19. J. Thromb. Haemost. 18, 1859–1865. doi: 10.1111/jth.14929
- Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., et al.
- (2020). Clinical characteristics and morbidity associated with coronavirus disease-2019 in a
- series of patients in metropolitan Detroit. JAMA Netw. Open. 3, e2012270. doi: 715
- 776 10.1001/jamanetworkopen.2020.12270
- 777 Tang, N., Li, D., Wang, X., and Sun, Z. (2020). Abnormal coagulation parameters are
- associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb.
- 779 Haemost. 18, 844-847. doi: 10.1111/jth.14768
- 780 Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., et al. (2020). ISTH
- interim guidance on recognition and management of coagulopathy in COVID-19. J. Thromb.
- 782 Haemost. 18, 1023-1026. doi: 10.1111/jth.14810
- Thoreau, B., Galland, J., Delrue, M., Neuwirth, M., Stepanian, A., Chauvin, A. et al. (2021).
- 784 D-Dimer levels and neutropils count as predictive and prognostic factors of pulmonary

r85 embolism in severe non-ICU COVID-19 patients. Viruses. 13, 758. doi: 725
r86 10.3390/v13050758

- 787 Van der Meijden, P.E.J., Heemskerk, J.W.M. (2019) Platelet biology and functions: new
- 788 concepts and clinical perspectives. Nature Rev. Cardiol. 16, 166-179.
- 789 https://doi.org/10.1038/s41569-018-0110-0
- 790 Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., et
- al. (2020). Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417–1418.
- 792 doi: 10.1016/S0140-6736(20)30937-5
- 793 Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., et al.
- (2016). Methods to estimate the between-study variance and its uncertainty in meta-analysis.
- 795 Res. Synth. Methods. 7, 55–79. doi: 10.1002/jrsm.1164
- 796 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020). Clinical characteristics of
- 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
- 798 JAMA. 323, 1061-1069. doi: 10.1001/jama.2020.1585
- 799 Wan, X., Wang, W., Liu, J., and Tong, T. (2014). Estimating the Sample Mean and Standard
- 800 Deviation from the Sample Size, Median, Range and/or Interquartile range. BMC Med. Res.
- 801 Methodol. 14, 1-13. doi: 10.1186/1471-2288-14-135
- Wang, P., Sha, J., Meng, M., Wang, C., Yao, Q., Zhang, Z., et al. (2020). Risk factors for
- severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective
- study. J. Transl. Med. 18, 1-12. doi: 10.1186/s12967-020-02655-8
- 805 Wang, Y., Yao, L., Zhang, J. P., Tang, P. J., Ye, Z. J., Shen, X. H., et al. (2020). Clinical
- 806 characteristics and laboratory indicator analysis of 67 COVID-19 pneumonia patients in
- 807 Suzhou, China. BMC Infect. Dis. 20,747. doi: 10.1186/s12879-020-05468-8

- 808 Welder, D., Jeon-Slaughter, H., Ashraf, B., Choi, S.-H., Chen, W., Ibrahim, I. et al. (2021).
- 809 Immature platelets as a biomarker for disease severity and mortality in COVID-19 patients.
- 810 Br. J. Haem. 194, 530-536. https://doi.org/10.1111/bjh.17656
- 811 White, D., MacDonald, S., Edwards, T., Bridgeman, C., Hayman, M., Sharp, M., et al.
- 812 (2020). Evaluation of COVID-19 coagulopathy: laboratory characterization using thrombin
- generation and nonconventional haemostasis assays. Int. J. Lab. Hematol. 43, 123-130. doi:
- 814 10.1111/ijlh.13329
- 815 Wong, R.S., Wu, A., To, K.F., Lee, N, Lam, C.W., Wong, C.K., et al. (2003).
- 816 Haematological manifestations in patients with severe acute respiratory syndrome:
- retrospective analysis. Br. Med. J. 326, 1358–62.
- 818 World Health Organization. (2013). Guidelines for investigation of cases of human infection
- 819 with Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
- 820 (https://cdn.who.int/media/docs/default-source/documents/emergencies/health-topics---
- 821 mers/mers_cov_investigation_guideline_jul132d7b61a0-a593-4527-8246-
- 25152b965baf.pdf?sfvrsn=3e2f6c65_1&download=true [Accessed September 30, 2021]
- 823 Wright, F.L., Vogler, T.O., Moore, E.E., Moore, H.B., Wohlauer, M.V., Urban, S., et al.
- 824 (2020). Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19
- infection. J. Amer. Col. Surgeons. 231, 193-203. doi: 10.1016/j.jamcollsurg.2020.05.007
- Xiong, M., Liang, X., and Wei Y.D. (2020). Changes in blood coagulation in patients with
- severe coronavirus disease 2019 (COVID-2019): a meta-analysis. Br. J. Haem. 189, 1050-
- 828 1052. doi: 10.1111/bjh.16725
- Yang, M., Ng, M. H., and Li, C. K. (2005). Thrombocytopenia in patients with severe acute
 respiratory syndrome. Hematology 10, 101–105. doi: 10.1080/10245330400026170

- 831 Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., et al. (2020). Thrombocytopenia and
- its association with mortality in patients with COVID-19. J. Thromb. Haemost. 18, 1469–72.
 doi: 10.1111/jth.14848
- 834 Yasuhara, J., Kuno, T., Takagi, H., and Sumitomo, N. (2020). Clinical characteristics of
- 835 COVID 19 in children: a systematic review. Pediatr. Pulmonol. 55, 2565-2575. doi:
 836 10.1002/ppul.24991
- 837 Yatim, N., Boussier, J., Chocron, R., Hadjadj, J., Philippe, A., Gendron, N. (2021). Platelet
- activation in critically ill COVID-19 patients. Ann. Intensive Care 11, 113.
 doi.org/10.1186/s13613-021-00899-1
- 840 Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., et al. (2020).
- 841 Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in

Singapore. JAMA 323, 1488-1494. doi: 10.1001/jama.2020.3204

- 843 Yu, C., Lei, Q., Li, W., Wang, X., Li, W., and Liu, W. (2020). Epidemiological and clinical 844 characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a 845 Public single-center experience. J. Infect. Health. 13, 1202-1209. doi: 846 10.1016/j.jiph.2020.07.002
- Yue, T., Zhou, W., He, J., Wang, H., Liu, Y., Wang, B., et al. (2021). Combined clinical and
- 848 imaging features better predict the critical outcomes of patients with SARS-COV-2. Medicine
- 849 100, e25083. doi: 10.1097/md.00000000025083
- 850 Zhang, A., Leng, Y., Zhang, Y., Wu, K., Ji, Y., Lei, S., et al. (2020). Meta-analysis of
- coagulation parameters associated with disease severity and poor prognosis of COVID-19.
- 852 Inter. J. Infect. Dis. 100, 441-448. doi: 10.1016/j.ijid.2020.09.021

- Zhang, H., Wang, X., Fu, Z., Luo, M., Zhang, Z., Zhang, K., et al. (2020). Potential factors
 for prediction of disease severity of COVID-19 patients. medRxiv [Preprint]. doi:
- 855 10.1101/2020.03.20.20039818
- 856 Zhang, J., Huang, X., Ding, D., and Tao, Z. (2021). Platelet-driven coagulopathy in COVID-
- 19 patients: in comparison to seasonal influenza cases. Exp. Hematol. Oncol. 10, 1-13. doi:
- 858 10.1186/s40164-021-00228-z
- Zhao, J., Zhu, M., Su, X., Huang, M., Yang, Y., Huang, J., et al. (2021). Clinical features and
- risk factors for severe-critically ill COVID-19 adult patients in Jiangsu, China. Medicine.
- 861 100, e24332. doi: 10.1097/md.00000000024332
- Zhao, Y., Yu, C., Ni, W., Shen, H., Qiu, M., and Zhao, Y. (2021). Peripheral blood
- inflammatory markers in predicting prognosis in patients with COVID-19. Some differences
- with Influenza A. J. Clin. Lab. Anal. 35, e23657. doi: 10.1002/jcla.23657
- Zheng, X., Chen, J., Deng, L., Fang, Z., Chen, G., Ye, D., et al. (2020). Risk factors for the
- 866 COVID-19 severity and its correlation with viral shedding: a retrospective cohort study. Int.
- 867 J. Infect. Dis. 93, 952-961. doi: 10.1002/jmv.26367
- Zhou, C., Huang, Z., Tan, W., Li, X., Yin, W., Xiao, Y., et al. (2020). Predictive factors of
- severe coronavirus disease-2019 in previously healthy young adults: a single-center,
- retrospective study. Respir. Res. 21:157, 1-8. doi: 10.1186/s12931-020-01412-1
- 871 Zhu, J., Pang, J., Ji, P., Zhong, Z., Li, H., Li, B. et al. (2020) Coagulation disfunction is
- associated with a severity of COVID-19. J. Med. Virol. 93, 962-972. doi: 10.1002/jmv.26336
- 873 Zwetsloot, P.-P., Naald, M.V.D., Sena, E.S., Howells, W.D., IntHout, J., De Groot, J.A.H. et
- al. (2017). Standardized means differences cause funnel plots distortion in publication bias
- assessments. eLife 6, e24260 DOI: 10.7554/eLife.24260

876 **Legends to the Tables**

- 877 **Table 1.** Summary of the effect sizes for all coagulation parameters
- 878 **Table 2.** Summary results of the sensitivity analysis
- 879 **Table 3.** Summary results of the subgroup analysis
- 880 **Table 4.** Egger's test for publication bias

881

882

883 **Legends to the Figures**

Figure 1. Flow diagram illustrating the process of data collection

Figure 2. Diagram depicting characteristics of selected studies: (A) number of publications

per country; (B) number of patients per country; (C) number of publications per severity

assessment criterion. The latter (C) indicates the total number of research articles to be 42

instead of 41 because one study reported two populations of patients admitted to the hospitalat different periods.

Figure 3. Forest plot of association between COVID-19 severity and (A) platelets; (B) Ddimers.

Figure 4. Forest plots of the association between COVID-19 severity and (A) fibrinogen; (B)

activated partial thromboplastin time; (C) prothrombin time.

Figure 5. GOSH diagnostic for influential cases in meta-analysis models (A) PLT; (B) Ddimers.

Figure 6. GOSH plots fixed for influential studies in meta-analysis models (A-B) fibrinogen; (C-E) - APTT, (F-I) - prothrombin time.

| 898 | Figure 7. | Contour-enhanced | funnel | plots | evaluating | the | presence | of | publication | bias | in | the |
|-----|-----------|------------------|--------|-------|------------|-----|----------|----|-------------|------|----|-----|
|-----|-----------|------------------|--------|-------|------------|-----|----------|----|-------------|------|----|-----|

- pool of articles that report association between COVID-19 severity and (A) platelets; (B) D-
- 900 dimers; (C) fibrinogen; (D) activated partial thromboplastin time; (E) prothrombin time.

901

902

903 Legends to Supplementary Materials

- 904 Supplementary File 1. Criteria for clinical severity of COVID-19 used by the National
- 905 Research Center for Cardiac Surgery.
- 906 Supplementary Table 1. Results of the NIH Quality Assessment.
- 907 Supplementary Table 2. Results of the Egger's test with Pustejovsky's corrected standard
 908 error.
- 909 Supplementary Figure 1. Exploring influential cases in meta-analysis models with Baujat
- 910 plots: (A) Platelets, (B) D-dimers, (C) Fibrinogen, (D) Activated partial thromboplastin time,

911 (E) Prothrombin time.

- 912 **Supplementary Figure 2.** Influence diagnostic of meta-analysis model for the association of
- 913 platelets count and COVID-19 severity.

914 Supplementary Figure 3. Influence diagnostic of meta-analysis model for the association of

915 D-dimers concentration and COVID-19 severity.

916 Supplementary Figure 4. Influence diagnostic of meta-analysis model for the association of
917 fibrinogen and COVID-19 severity.

918 **Supplementary Figure 5.** Influence diagnostic of meta-analysis model for the association of

- activated partial thromboplastin time and COVID-19 severity.
- 920 Supplementary Figure 6. Influence diagnostic of meta-analysis model for the association of
- 921 prothrombin time and COVID-19 severity.
- 922 Supplementary Figure 7. Search for influential cases by leave-one-out method in meta-

analysis models for the association of (A) platelets count, (B) D-dimers and COVID-19severity.

- 925 Supplementary Figure 8. Search for influential cases by leave-one-out method in meta-
- analysis models for the association of (A) fibrinogen, (B) APTT and COVID-19 severity.

927 Supplementary Figure 9. Search for influential cases by leave-one-out method in meta-

analysis model for the association of prothrombin time and COVID-19 severity.

929 Supplementary Figure 10. Forest plots of association of COVID-19 severity and (A)
930 platelets count and (B) D-dimers with outliers removed.

931 Supplementary Figure 11. Forest plots of association of COVID-19 severity and (A)

fibrinogen, (B) activated partial thromboplastin time, and (C) prothrombin time with outliersremoved.

Supplementary Figure 12. Exploring the influence of meta-analysis study composition on
heterogeneity and pooled effect size: (A) fibrinogen, (B) activated partial thromboplastin
time, and (C) prothrombin time.

937 Supplementary Figure 13. Results of three clustering methods (A) K-means, (B) DBSCAN,
938 and (C) Gaussian Mixture on the meta-analysis model for association of fibrinogen and
939 COVID-19 severity.

- 940 Supplementary Figure 14. Results of three clustering methods (A) K-means, (B) DBSCAN,
- 941 and (C) Gaussian Mixture on the meta-analysis model for association of activated partial
- 942 thromboplastin time and COVID-19 severity.
- 943 Supplementary Figure 15. Results of three clustering methods (A) K-means, (B) DBSCAN,
- and (C) Gaussian Mixture on the meta-analysis model for association of prothrombin time
- and COVID-19 severity.
- 946 Supplementary Figure 16. Exploring presence of publication bias with corrected funnel
- 947 plots: SMD plotted against sample size-based precision estimate: (A) platelets, (B) D-dimers,
- 948 (C) fibrinogen, (D) activated partial thromboplastin time, (E) prothrombin time.